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Abstract 
The application of human embryonic stem cells (hESCs) in regenerative medicine has 
remained challenging in the last decade, mainly due to potential teratoma formation of 
undifferentiated hESCs upon administration in vivo. To remove undifferentiated hESCs from 
the differentiated ones, Bioprocessing Technology Institute (BTI) has generated a mouse 
hybridoma immunoglobulin M, IgM 84 that exhibits cytotoxic activity via oncosis towards 
undifferentiated hESCs that are not observed in other IgMs such as IgM 85. Previous findings 
have shown that IgM 84 and 85 bind to the same surface antigen on undifferentiated hESCs, 
i.e. podocalyxin-like protein-1. Using comparative modeling, we showed that the 3-
dimensional (3D) models for the variable regions of IgM 84 and 85 are not significantly 
different in structure despite major differences within their complementarity determining 
regions (CDRs). On the other hand, using techniques such as matrix-assisted laser 
desorption/ionization mass spectrometry, high pH anionic exchange chromatography etc., we 
found that IgM 84 to be differently N-glycosylated i.e. improper trimming of high mannose 
type N-glycans in endoplasmic reticulum (ER), and less fucosylation and sialylation of 
complex type N-glycans in Golgi, as compared to those on IgM 85. We believe that these 
differences might suggest a differently folded IgM 84 that could shed more light on how 
multivalent IgM 84 exhibits its cytotoxicity activity.  
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IgM 84 and 85
1
 are immunoglobulins (Ig) M generated by the Stem Cell (SC) group 
at the Bioprocessing Technology Institute (BTI), that bind to the surface antigen, 
podocalyxin-like protein-1 (PODXL) on undifferentiated human embryonic stem cells 
(hESCs). Interestingly, only IgM 84 exhibits cytotoxic activity via oncosis towards these 
undifferentiated hESCs (Choo et al., 2008; Tan et al., 2009). Using antibody fragments
2
, it 
has been shown that binding to antigen sites alone are not sufficient to initiate cytotoxic 
activity to the same level that was previously observed in pentameric IgM 84 thus suggesting 
the importance of its multivalency in oncosis (Lim et al., 2011). In this thesis, we were 
interested (i) to examine if N-glycosylation differences between IgM 84 and 85 could explain 
the cytotoxic behaviour in multivalent IgM 84; and (ii) to create 3D structural models for 
variable regions of IgM 84 and 85 and visualize the structural differences on their antigen 
binding sites. 
Using our mouse N-glycan library
3
, N-glycans structures were assigned to different 
mass ions of IgM 84 and 85. We categorized all the N-glycan structures into three main 
groups – high mannose, biantennary and triantennary complex types and we found several 
unique complex type N-glycan structures in the respective mass spectra of IgM 84 or 85. In 
high mannose type, the presence of Man9GlcNAc2 in IgM 84 but not in IgM 85, indicates the 
possibility of a differently folded IgM 84 exiting endoplasmic reticulum (ER) because N-
glycosylation plays a vital role in ER protein folding mechanism. In addition, IgM 84 seems 
to be less fucosylated compared to IgM 85 due to the presence of various non-fucosylated 
complex type N-glycans in the mass spectrum of IgM 84 but not that of IgM 85. A different 
folded IgM 84 exiting ER may cause these structures to be shielded from fucosylation during 
                                                     
1
 The registered names for commercial use assigned to IgM 84 and 85 are mAb 84 and 85, respectively.  
2
 Four antibody fragment formats are generated namely Fab 84, scFv 84, scFv 84-diabody and scFv 84-
HTH 
3
 Mouse N-glycan library was a consolidation of the most mouse N-glycan profiling from Consortium 




late processing or maturation step of N-glycans in the trans-Golgi. Furthermore, sialylation 
which is another maturation step of N-glycans, was observed to be less in IgM 84. Besides, 
IgM 85 also possesses two trisialylated complex type N-glycans that was not observed in IgM 
84.  
IgM 84 and 85 were found to differ mostly in the primary sequences within their 
variable regions i.e. about 57.8% sequence similarity, especially in their complementarity 
determining regions (CDRs). Despite these differences, the 3D models for variable regions of 
IgM 84 and 85 showed only minimal differences between their antigen binding sites, 
substantiated by the low root mean square difference (RMSD) values i.e. 1.51 Å and 1.27 Å 
for variable heavy and light chains respectively, upon superimposition. Differences observed 
around loop or flexible regions between two -sheets, are not enough to result in a significant 
structural difference between the antigen binding sites of IgM 84 and 85. 
In conclusion, with the lack of evidence that the antigen binding sites of IgM 84 and 
85 are different structurally, we propose that a potentially different protein conformation in 
IgM 84 due to differences in N-glycosylation maturation may help to explain the cytotoxic 






N.1  General Abbreviations and Nomenclature 
ADCC antibody-dependent cell-mediated cytotoxicity 
ALG genes asparagine linked glycosylation genes 
BCR B cell receptor 
CDC complement dependent cytotoxicity 
CDP cytidine diphosphate 
CDR complementarity determining regions 
CFG Consortium for Functional Glycomics 
CH1, CH2 and CH3  constant regions 1, 2 and 3 of heavy chains 
CID collision-induced dissociation 
CL constant regions of light chains 
CNX calnexin 
CRT calreticulin 
CTP cytidine triphosphate 
CV column volume 
Dol-P-P-GlcNAc  dolichol-P-P-N-acetylglucosamine 
ECL enhanced chemiluminescence 
EDEM ER degradation-enhancing α-mannosidase I–like protein 
EMEA European Medicines Agency 
EPO erythropoietin 
ER endoplasmic reticulum 
Erp endoplasmic reticulum protein 
ESI-MS electrospray ionization-mass spectrometry 
Fab fragment, antigen binding 




Fc fragment, constant 
FDA United States Food and Drug Administration 
Fruc fructose 
Fuc fucose 
Fv fragment, variable 
Gal galactose 
GalNAc N-Acetylgalactosamine 
GBPs glycan binding proteins 























GPI anchor glycosylphosphatidylinositol anchor 
GTP guanosine triphosphate 
hESCs human embroynic stem cells 
HPAEC-PAD 
 
high pH anionic exchange chromatography-pulsed 
amperometric detection 




HTD hot trypsin digestion 
ICH International Conference on Harmonization 
IgA, IgD, IgE, IgG & IgM immunoglobulin A, D, E, G and M 
LacNAc N-acetyllactosamine 
LC-MS liquid chromatography-mass spectrometry 
MALDI-MS matrix-assisted laser desorption/ionization-mass spetrometry 
MALDI-TOF matrix assisted laser desorption/ionization-time of flight 
MALDI-TOF-TOF 
 
matrix assisted laser desorption/ionization-time of flight-time 
of flight 
Man mannose 
MEKC micellar electrokinetic chromatography 
mRNA messenger ribonucleic acid 
MS mass spectrometry 
MWCO molecular weight cutoff 
N/A not applicable 
Neu5Ac N-Glycolylneuraminic acid 
Neu5Gc N-Acetylneuraminic acid 
NMR nuclear magnetic resonance 
OST oligosaccharyltransferase 
PEG polyethylene glycol 
PI phosphatidylinositol 
PODXL podocalyxin-like protein 1 
RMSD root mean square difference 
scFv 84-HTH single chain variable fragment 84-helix turn helix 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEC size exclusion chromatography 




UDP uridine diphosphate 
UMP uridine monophosphate 
VH variable regions of heavy chains 
VL variable regions of light chains 
 
N.2 Abbreviations for bioinformatics 
PDB Protein Data Bank 
PDB_nr95 Protein Data Bank_non redundance 95% 
SCOP Structural Classification of Proteins 
DALI Distrance matrix alignment 
CATH Class, Architecture, Topology and Homologous 
BLAST Basic Local Alignment Search Tool 
PSI-BLAST 
 
Position Specific Iteractive-Basic Local Alignment Search 
Tool 
BLOSUM BLOcks of Amino Acid SUbstitution Matrix 
PAM Point Accepted Mutation 
MD Molecular Dynamics 
PDF Probability Density Function 
DOPE Discrete Optimized Protein Energy 
 
N.3 List of chemicals 
ACN acetonitrile 
-cyano -cyano-4-hydroxycinnamic acid 





DHB 2,5-dihydroxy benzoic acid 
DMSO dimethyl sulfoxide 
DTT dithiothreitol 
EDTA ethylenediaminetetraacetic acid 
GdnHCl guanidine hydrochloride  
HCl hydrochloride acid 
IAA iodoacetamide 
NaCl Sodium chloride 
NaN3 Sodium azide 
NaOH  Sodium Hydroxide 
NH4HCO3 ammonium bicarbonate 
PNGase F, A peptide-N-glycosidase F, A 
PVDF polyvinylidene fluoride 
TBS tris-buffered Saline  
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1.1.1 Human embryonic stem cells 
Human embryonic stem cells (hESCs) are pluripotent stem cells that are derived from 
the inner cell mass of the blastocyst during the early-stage of an embryo (Thomson et al., 
1998). A pluripotent cell is one that is able to differentiate into all derivatives of three primary 
germ layers - ectoderm, endoderm, and mesoderm, which include more than 220 cell types in 
the adult body (Thomson et al., 1998). Under defined conditions, hESCs are capable of 
propagating indefinitely, which makes them a useful tool for regenerative medicine
1
 in 
research and applications include some of the most common neural diseases such as 
Parkinson’s disease, stroke and multiple sclerosis (Lindvall and Kokaia, 2006).  
However, one major issue with using hESCs in regenerative medicine is its potential 
to form teratomas from remnants of undifferentiated hESC upon administration (Knoepfler, 
2009). Such safety issue poses a major roadblock to using hESCs as therapeutics. With regards 
to cell-cell separation methods, there have been major efforts done in the last decade including 
work by Schriebl and co-workers from our institute, who used stage-specific embryonic 
antigen 1 (SSEA-1) on undifferentiated mESCs as selection marker to remove them from the 
pool of differentiated mESCs using highly selective magnetic activated cell sorting method 
(Schriebl et al., 2010). The work highlighted the limitation of engineering approach to achieve 
stringent therapeutic requirement
2
 of using hESCs that could possibly be done otherwise using 
specific binding antibodies, better still if these antibodies exert cytotoxicity against them 
(Schriebl et al., 2012)  
                                                     
1
 Regenerative medicine is a processing of replacing lost or restoring damaged cells, tissues or organs 
back to normal functions 
2
 A log clearance rate of 10 is required to reach a safety margin of 10
-1
 undifferentiated hESCs or a 








1.1.2 Discovery of monoclonal antibodies against undifferentiated hESC 
At the Bioprocessing Technology Institute (BTI), the Stem Cell group has generated a 
panel of 10 monoclonal antibodies (mAbs)
 
against surface antigens on undifferentiated hESCs 
of HES-3
1
 cell lines, following immunization of Balb/C mice using the entire HES-3 cells 
(Choo et al., 2008). Two of these mAbs, licensed as mAb 84 and 85, were found to bind to the 
same surface antigen on undifferentiated hESCs, i.e. podocalyxin-like protein-1 (POXDL). In 
this thesis, mAb 84 and mAb 85 will be referred to as IgM 84 and IgM 85, respectively, to 
emphasize that both antibodies are of the immunoglobulin M isotype.  
Interestingly, IgM 84 not only binds but also exhibits cytotoxicity against 
undifferentiated hESC. The reported cell death caused by IgM 84 is termed oncosis, which is 
different from apoptosis, triggered by antibody-dependant cell mediated cytotoxicity (ADCC). 
Oncosis, as described by Tan and co-workers (Tan et al., 2009), is a form of cell death that is 
preceded by cell aggregation and damage to cell membranes of the undifferentiated hESCs, 
causing leakage of intracellular Na
+
 ions. The proof of such cell killing mechanism is revealed 
under scanning electron microscope by pore formation in the cell membrane of 
undifferentiated hESCs due to the clustering of PODXL-1 antigens (Tan et al., 2009).  
Lim and co-workers engineered antibody fragments from IgM 84 and showed that only 
scFv
2
 84-HTH, a fragment that is bivalent and highly flexible, could recapitulate the cytotoxic 
effect of IgM 84
3
, while other fragments, scFv 84, scFv 84 diabody, and Fab 84, that are 
monovalent or bivalent and more rigid only bound to PODXL (Lim et al., 2011). Moreover, 20 
times more of scFv 84-HTH in quantity was required to achieve the same level of cytotoxicity 
as IgM 84 (Lim et al. 2011). These findings highlights the importance of the unique structure 
of IgM 84 that allows cross-linking of multiple PODXL-1 antigens on the cell surface thus 
triggering efficiently cell death in hESCs via oncosis. 
                                                     
1
 HES-3: Human embryonic stem cell lines obtained from ES Cell International (ECI, Singapore, 
http://www.escellinternational.com) 
2
 scFv stands for single-chain variable fragment, a fusion protein of variable regions of heavy (VH) and 
light chains (VL) of immunoglobulins 
3
 In the article by Lim and co-workers, IgM 84 is referred to as mAb 84 instead, which is the licensed 




N-glycosylation is a biosynthetic process of adding glycans or sugar moieties to the 
protein backbone of proteins such as immunoglobulins via asparagine linked N-glycosidic 
linkages. The roles of N-glycosylation in biological activities of immunoglobulins G and M as 
effectors functions and complement have previously been reported (Wright et al., 1990; 
Wormald et al., 1991; Mimura et al., 2000; Anthony et al., 2008). Hence, we would like to 
explore if N-glycosylation of IgM 84 results in a different protein conformation that causes 
IgM 84 to be cytotoxic against undifferentiated hESCs. 
 
1.2 Thesis Scope 
The aim of this thesis is two-fold: a) to study the N-glycosylation of IgM 84 and 85 and 
to examine if any of the differences in N-glycan types between IgM 84 and 85 could explain 
the cytotoxic effect of IgM 84, as described in Section 1.2.1; b) to model the variable regions 
of IgM 84 and 85 and to examine specifically if there is any structural difference between the 
antigen binding sites of IgM 84 and 85, as described in Section 1.2.2. 
1.2.1 Comparative N-glycosylation analysis of IgM 84 and 85 
IgM 84 and 85 have been previously generated using hybridoma technology, 
subsequently adapted step-wise and cultured in protein-free, chemically defined media in 5L 
continuous stirred tank bioreactor (Lee et al., 2009). Cultures in bioreactors were harvested 
and clarified by centrifugation and depth filtration, before they were purified in two steps – 
PEG precipitation and Anion-Exchange Chromatography (Tscheliessnig et al., 2009).  
Starting from the purified IgM 84 and 85, the N-glycans were released, fractionated 
and analysed using MALDI-TOF MS. Meanwhile, we built a mouse N-glycan library, from 
the CFG database to match and assign relevant N-glycan structures to different mass peaks. 
We performed comparative analysis of the global N-glycan profiling and degree of sialylation 
of IgM 84 and 85. We also did a preliminary study on the site-specific N-glycan profiling of 




1.2.2 Visualization of variable binding regions of IgM 84 and 85 
We developed and superimposed the 3D structural models for variable regions of IgM 
84 and 85 i.e. variable heavy and light chains separately, to visually inspect for any structural 
differences within the antigen binding sites. Upon superimposition, we also calculated the root 
mean square difference (RMSD) to quantify the spatial structural differences. 
1.2.3 Thesis Organization 
Chapter 2 starts with an introduction on immunoglobulin (Ig) in general, and IgM in 
particular. The chapter then follows with an overview of the types of N-glycan present in 
mouse hybridoma IgM and the biosynthetic pathway of N-glycans including different terminal 
structures of N-glycans that are commonly found in mammals. The last part of this chapter will 
touch on the therapeutic role of Ig and how N-glycosylation plays an important role in this 
aspect. In Chapter 3, we will discuss our approaches to study the N-glycosylation of IgM 84 
and 85 with regards to their macro- and microheterogeneity, the overall percentages of 
sialylation and distribution, the presence of glyco-epitopes in IgM 84 and 85, and the process 
to construct 3D structural models for variable regions of IgM 84 and 85 using Discovery 
Studio software. Chapter 4 then presents the results of comparative analysis of IgM 84 and 85 
in terms of global N-glycan profiling and sialylation analysis, and the possible implications 
will also be discussed. In addition, the constructed 3D structural models are superimposed to 
visually inspect if there are any differences between IgM 84 and 85 on their antigen binding 
sites. The concluding chapter, Chapter 5, provides a summary of the main conclusions, and 
recommendations for future works. 
Appendix A shows information regarding the amino acid sequence of heavy and light 
chains of IgM 84 and 85, the sequence alignment results of the corresponding constant and 
variable regions, and the respective potential N-glycosylation sites on each chain. Appendix B 
lists down the resources obtained from Consortium for Functional Glycomics (CFG) to 
construct our in-house mouse N-glycan library. Appendix C shows a list selected of peptide 




glycopeptides for site-specific N-glycan profiling studies. Appendix D shows the masses, 
structures, percentages of relative abundance and distribution of all N-glycan structures 





2 LITERATURE REVIEW 
2.1 Immunoglobulins (Ig) 
Ig, also known as antibody
1
, is based on a single large Y-shaped protein (Figure 2.1), 
produced by our immune system to identify and neutralize foreign organisms like bacteria and 
viruses. Such identification is performed through recognition of a unique part on the foreign 
objects that is called antigen (Janeway, 2001). Antigen-binding site of an antibody is termed 
paratope, whereas the site on an antigen where the antibody binds is called epitope.  
 
Figure 2.1 Immunoglobulin (Ig) G consists of two heavy chains (VH, CH1, CH2 and CH3) and two 
light chains (VL and CL) connected by disulphide bonds (red). It has one site for carbohydrate 
(blue) attachment on each heavy chain 
 
Immunoglobulins (Ig) can be broadly classified into 5 isotypes or classes – IgA, IgD, 
IgE, IgG and IgM. The prefix Ig stands for immunoglobulin; whereas the capital letter i.e. A, 
D, E, G and M indicates the type of heavy chain each isotype possesses, as denoted in similar 
Greek letters and respectively. In mammals, there are two types of light chains 
across all Ig isotypes i.e.  and . One Ig monomer consists of four polypeptide chains; two 
heavy chains (H) and two light chains (L) connected by disulfide bridges. Each heavy and light 
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 Antibody can be either monoclonal or polyclonal, which describes its ability to recognize and bind 




chain has two regions, the constant region
1
 (C) and the variable region
2
 (V). The constant 
region is largely similar for Ig of the same isotype coming from the same source.  
In one Ig monomer, there are Fab, Fv and Fc parts that describe the non-covalent 
association between different domains of heavy and light chains. Fab is the region where 
domains VL, CL, VH and CH1 associate; Fc is the region where domains CH2 and CH3 from each 
heavy chain associate; and Fv is the region of VL and VH and it is most important region of an 
antibody for binding to antigens. Near the tip of Fv lie the CDRs which stand for 
complementarity determining regions. More specifically, they are regions of variable loops of 
-strands, three3 on each of the variable light (VL) and heavy (VH) chains that are responsible 
for epitope recognition a specific antigen. 
 
2.1.1 Immunoglobulin (Ig) M 
 
Figure 2.2 Structure of a pentameric mouse IgM (Perkins et al., 1991) 
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 Constant region of heavy chain is made up of three domains i.e. CH1 CH2 and CH3for heavy chain; 
whereas for light chain, it only has one i.e. CL.  
2
 Variable region of heavy and light chains are VH and VL respectively 
3




Antibodies are produced by white blood cells in either soluble form - secreted out of the 
cell, or membrane-bound - attached to the surface of a B cell or B cell receptor (BCR). These 
BCR facilitate the activation and subsequent differentiation of B cells into antibody-producing 
plasma cells or memory B cells that will survive and remain dormant but able to recognize the 
same antigen faster in future immune response.  
Immunoglobulin M or IgM is the first antibody isotype produced in B cells in response 
to initial immune response to antigen. In our case, IgM 84 and 85 are produced in our mouse 
hybridoma clones. IgM is the largest immunoglobulin (Ig) among all other isotypes. IgM that 
is secreted by B cells can exist predominately as pentamer, but also hexamer. A pentameric 
IgM has a protein size of approximately 900kD and is made up of 5 Ig monomers that are 
connected by disulphide bridges (Figure 2.2). Besides, a pentameric IgM also has a J-chain 
that is absent in hexameric IgM. One distinct physical characteristic of an IgM from all other 
isotypes is the presence of a vast number of N-glycosylation sites. In mouse IgM, there can be 
between 5 to 6 N-glycosylation sites on the heavy chain, 0 to 1 on the light chain, and 0 to 1 on 
the J-chain. 
 
2.2 N-glycosylation of Immunoglobulins (Ig)  
2.2.1 Carbohydrates and Glycoproteins 
Carbohydrates
1
 are one major class of molecules that make up a cell, tissue, organ, 
physiological system, and eventually an intact organism, besides proteins, nucleic acids and 
lipids. Like these other molecules, carbohydrates also encompass a crucial role in biological 
activities as intermediates in generating energy and as signalling effectors, recognition 
markers, and structural components (Varki and Sharon, 2009). Carbohydrates are polymers of 
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 Also commonly known as sugars, oligosaccharides or glycans when they are attached to a protein 




monosaccharides (Figure 2.3) that are joined together via glycosidic linkages. Therefore, they 
are sometimes referred to as oligosaccharides.  
 
 
Figure 2.3 Open chain (left) and ring form (right) of D-galactose  
In nature, several hundred distinct monosaccharides are known to occur; in mammals, 
there are only six monosaccharide types that are categorized as follows: 
 Pentoses: Five-carbon neutral sugars; 
 Hexoses: Six-carbon neutral sugars; 
 Hexosamines: Hexoses with an amino group at the 2-position, which can be either free 
or, more commonly, N-acetylated; 
 Deoxyhexoses: Six-carbon neutral sugars without the hydroxyl group at the 6-position; 
 Uronic acids: Hexoses with a negatively charged carboxylate at the 6-position; 
 Sialic acids: Family of nine-carbon acidic sugars.  
Glycoproteins are proteins which contain oligosaccharide chains, or glycans covalently 
attached to the protein backbone. The glycan is synthesized and attached to the protein either 
through co- or post-translational modification, of which a process that is known as 
glycosylation. Most glycans can be attached to side chains of proteins via three types of 




Table 2.1 Monosaccharides commonly found in mammalian glycoproteins  
No Monosaccharide Type Abbreviation Symbol 
1 D-Glucose Hexose Glc 
 
2 D-Galactose Hexose Gal 
 
3 D-Mannose Hexose Man 
 
4 L-Fucose Deoxyhexose Fuc 
 
5 N-Acetylgalactosamine Hexosamine GalNAc 
 
6 N-Acetylglucosamine Hexosamine GlcNAc 
 
7 N-Acetylneuraminic acid Sialic Acid Neu5Ac 
 
8 N-Glycolylneuraminic acid Sialic Acid Neu5Gc 
 
 
2.2.1.1 Glycosylphosphatidylinositol (GPI) anchor 
A GPI anchor is a glycolipid that is attached to the C-terminus of a protein and the 
lipid bilayer of cell membrane via two phosphodiester linkages of phophoethanolamine and 
phosphatidylinositol (PI), respectively (Figure 2.4). Such structure constitutes the only anchor 
to the lipid bilayer of cell membrane and it is important for the function of membrane bound 
protein in the extracellular space. Defects in GPI anchor is linked to various rare diseases such 






Figure 2.4 GPI anchor connects C-terminus of protein to membrane lipid bilayer via two 
phosphodiester linkages of phosphoethanolamine and phosphatidylinositol, respectively. 
R1=Man(1-2); R2,R3=Phosphoethanolamine; R4=Gal4; R5=GalNAc(1-4); R6=Fatty Acid at C2 or 
C3 of inositol (Adapted from GPI Anchor Structure found in www.sigmaaldrich.com) 
 
2.2.1.2 O-linked glycan or O-glycan  
An O-linked glycan is an oligosaccharide structure covalently -linked to a 
glycoprotein via N-acetylgalactosamine (GalNAc). Typically, O-glycan is attached to the 
hydroxy oxygen of a serine (Ser or S) or threonine (Thr or T) residue of glycoprotein by an O-
glycosidic bond that can be extended into a variety of different structural core classes. O-
glycans, also called O-GalNAc glycans, are often found in mucins, glycoproteins with high 
content of serine, theorine, and proline residues. O-glycans of mucins are essential for their 
ability to hydrate and protect the underlying epithelium by trapping bacteria via specific 
receptor sites within O-glycans. In addition, these hydrophilic and negatively charged O-
glycans also promote binding of water and salts that cause mucus to be viscous, forming a 




2.2.1.3 N-linked glycan or N-glycan 
A N-glycan is an oligosaccharide structure that is covalently linked to an asparagine 
(Asn or N) residue of a protein. Such linkage commonly involves a GlcNAc sugar unit of the 
oligosaccharide and it is mostly found within the consensus peptide sequence of Asn-X-
Ser/Thr
1
. Recent reports also suggest N-glycans to be found on Asn-X-Cys sequon in 
mammals, yeast and plants (Sato et al., 2000; Gil et al., 2009; Matsui et al., 2011). N-Glycans 
share a common pentasaccharide core (Man3GlcNAc2) that can be further extended into three 
main general classes: high-mannose (oligomannose) type, complex type, and hybrid type 
(Figure 2.5). In reality, a much diverse pool of oligosaccharide structures is found under each 
N-glycan type than those presented in Figure 2.5. From the perspective of a single protein 
molecule, the variable site occupancy or variability in location and number of glycosyl 
attachment sites is called macroheterogeneity; and variability in oligosaccharide structure at 
specific glycosylation sites is called microheterogeneity. Furthermore, higher number of 
potential N-glycosylation sites can add into the complexity and heterogeneity of the 
glycoprotein.  
 
Figure 2.5 High mannose, complex and hybrid types are three typical N-glycan types found in 
mammals. Each structure here is just the representation that each N-glycan type could have. 
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As previously mentioned, immunoglobulin M (IgM) is highly N-glycosylated protein 
molecule bearing potential N-glycosylation sites of 5 to 6 on one heavy chain. One pentameric 
IgM molecule could have between 50 and 60 potential N-glycosylation sites and in certain 
cases, light chains of IgM were reported to sometimes bear 1 potential N-glycosylation site as 
well (Perkins et al., 1991). Due to this massive structure, only a handful of literature has 
successfully demonstrated using chemical cleavage method and nuclear magnetic resonance 
(NMR) (Chapman and Kornfeld, 1979; Chapman and Kornfeld, 1979; Brenckle and Kornfeld, 
1980; Anderson et al., 1985; Monica et al., 1995). However, results that have been shown for 
mouse IgM in these reports still lacked the comprehensiveness of a full glycan profile that one 
might desire. While human serum IgM glycosylation has been recently characterized (Arnold 
et al., 2005), a full N-glycan profiling for mouse IgM has not yet been completely reported.  
Because of the presence of such much N-glycans in the IgM and before we proceed to 
characterize N-glycosylation of our IgM 84 and 85, it would be worthwhile to spend some 






2.3 Biosynthesis of N-Glycans 
N-glycans are covalently attached to proteins at asparagine (Asn) residues of 
glycoprotein backbone by an N-glycosidic bond. There are five different N-glycan linkages
1
 
that have been reported, of which N-acetylglucosamine linkage to asparagines (GlcNAc1-
Asn) is the most common (Stanley et al., 2009). 
 
2.3.1 Synthesis of Dolichol-P-P-oligosaccharide2 precursor 
The biosynthesis of eukaryotic N-glycans begins with the synthesis of dolichol 
pyrophosphate N-acetylglucosamine (Dol-P-P-GlcNAc) on the cytoplasmic face of membrane 
of Endoplasmic Reticulum (ER), where GlcNAc-P is first transferred from UDP-GlcNAc to 
lipid-like precursor dolichol phosphate (Dol-P) (Figure 2.6). 
 




Figure 2.6 shows the overall process of how subsequent thirteen sugars
2
 are 
sequentially added by a series of enzymatic reactions to Dol-P-P-GlcNAc to form 
Glc3Man9GlcNAc2-P-P-Dol prior to its en-bloc transfer to Asn-X-Ser/Thr sequon of a nascent 
protein by oligosaccharyltransferase (OST). It is worth noting that the entire reactions do not 
just take place on the cytoplasmic face of ER. When Dol-P-P-GlcNAc is extended to 
Man5GlcNAc2-P-P-Dol, it is being “flipped” across the ER membrane and therefore the rest of 
the reactions take place inside the ER lumen, including the en-bloc transfer. Enzymes that are 
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 Other linkages are gluose, N-acetylgalactosamine (GalNAc), rhamnose, and linkage to argine: glucose 
2
 Glycan – Glc3Man9GlcNAc2 is made up of two sugar units of N-acetylglucosamine (GlcNAc), nine 




involve in adding the sugar units are encoded by ALG
1
 while the sugar units that are being 
added are transferred directly from UDP-GlcNAc and GDP-Man on the cytoplasmic face; and 
indirectly via Dol-P-Man and Dol-P-Glc inside the ER lumen (Figure 2.7). Meanwhile, the 
nascent protein is synthesized in the ribosome and translocated into the ER lumen co- 
translationally.  
 
Figure 2.7 Synthesis of Glc3Man9GlcNAc2-P-P-Dol starts on the cytoplasmic face of ER where 
Dol-P-P-GlcNAc is extended to Man5GlcNAc2-P-P-Dol before it is being “flipped” onto the luminal 
face of ER. After that, more glucose and mannose sugars are added to form the full 14-sugar N-
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 ALG genes stand for asparagine linked glycosylation genes, identified primarily from the studies of 




2.3.2 Biosynthesis of N-glycan types 
 
Figure 2.8 Once transferred, the oligosaccharide precursor Glc3Man9GlcNAc2 is being trimmed 
sequentially to Man8GlcNAc2 in ER lumen prior to the export of the glycoprotein to the Golgi 
apparatus. In the cis-Golgi, trimming process continues until Man5GlcNAc2 the basic structure for 
synthesizing hybrid and complex N-glycan types, is formed. If the second trimming process is 
escaped, high mannose N-glycan types will be present on the secreted mature glycoprotein. In 
medial-Golgi, GlcNAc sugar units are added to the core and two Man sugar units are removed 
prior to maturation steps like galactosylation, fucosylation and sialylation. of N-glycans in the late 







In a nutshell, following the en-bloc transfer, the Glc3Man9GlcNAc2 N-glycan 
precursor is initially trimmed to the Man5GlcNAc2 – basic structure for synthesizing complex 
and hybrid N-glycans, via a series of enzymatic reactions catalyzed by membrane-bound 
glycosidases in ER and cis-Golgi followed by the subsequent addition of other sugar units by 
glycosyltransferases in cis-, medial- and trans-Golgi (Figure 2.8). The expression of these 
trimming glycosidases has been quite conserved across eukaryotes and is known to interact 
with ER chaperones that recognize specific features of the trimmed N-glycan, that result in 
different protein folding in the ER. Details on this process will be discussed in following 
Section 2.3.4. 
In the first stage of the trimming process, three glucoses are removed from 
Glc3Man9GlcNAc2 sequentially by -glucosidases I and II, which act specifically to remove 
one 1-2Glc and two 1-3Glc residues, respectively. Majority of glycoproteins exit ER en 
route to the cis-Golgi, carrying Man8-9GlcNAc2 depending if they have been acted on by ER α-
mannosidase I which specifically cleaves off terminal 1-2Man. A second α-mannosidase I–
like protein, also called EDEM (ER degradation-enhancing α-mannosidase I–like protein), is 
important in the recognition of misfolded glycoproteins, thereby targeting them for ER 
degradation (Freeze et al., 2009). 
Further trimming of α1-2Man residues continues with the action of α1–2 mannosidase 
I in the cis-Golgi to give Man5GlcNAc2 (Figure 2.8). However, part of the Man8-9GlcNAc2 
may escape modifications by the mannosidase I that results in a range of high-mannose type 
N-glycans i.e. Man5-9GlcNAc2 on the mature secreted glycoproteins. Biosynthesis of hybrid 
and complex type N-glycans begins in the core Man5GlcNAc2 with the addition of GlcNAc 
residue to C-2 of the mannose α1-3, initiated by a N-acetylglucosaminyltransferase I, also 
called GlcNAcT-I, to form GlcNAcMan5GlcNAc2. Following this step, two mannose residues 
i.e. α1-3Man and α1-6Man can then be removed by -mannosidase II, inside medial-Golgi to 
form GlcNAcMan3GlcNAc2 (Figure2.8). Afterwards, a second GlcNAc is added to C-2 of the 




type N-glycans. However, if the two mannose residues are not removed, no further 
modification could occur in that mannose α1–6 branch leading to the formation of hybrid type 
N-glycans instead. These hybrid type N-glycans may occasionally carry “bisecting” GlcNAc 
(as indicated by red arrow in Figure 2.9). Further modification in the other branch by adding 
different terminal structures is still possible and will be discussed in Section 2.3.3. 
 
Figure 2.9: Branching of complex type N-glycans (Adapted from Essentials of Glycobiology, 2nd edition) 
In complex type N-glycans, additional branches
1
 can be extended at C-4 of the core 
mannose α1-3 (by GlcNAcT-IV) and C-6 of the core mannose α1-6 (by GlcNAcT-V) to yield 
tri- and tetra-antennary ones. Further branching reactions to form highly branched hepta-
antennary structures by other enzymes such as GlcNAcT-IX, GlcNAcT-VB and GlcNAcT-XI 
(Figure2.9) are also possible in birds and fish, but not mammals. Besides hybrid type, complex 
type N-glycans may also carry a “bisecting” GlcNAc that is attached to the -mannose of the 
core structure by GlcNAcT-III after the actions of adding second GlcNAc residue to the core 
by GlcNAcT-II (Figure 2.9). The presence of this “bisecting” GlcNAc could therefore inhibit 
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further actions of GlcNAcT-IV and GlcNAcT-V to create more branches from the core 
(Figure2.9).  
 
2.3.3 Maturation of N-Glycans 
Final maturation of the N-glycans occurs in the trans-Golgi (Figure 2.8), converting 
the limited repertoire of hybrid and branched N-glycans into extensive array of mature, 
complex N-glycans. The first step of maturation is typically  1-4 galactosylation – adding one 
galactose residue linked in  1-4 to each of the existing branching GlcNAc of the antenna. 
Following this step, four major modifications – fucosylation, sialylation, 1,3 galactosylation 
and elongation of LacNAc tandem repeats, are widely observed in mammals.  
Fucosylation: Addition of fucose residue via a) 1-6 linkage to Asn-linked N-
acetylglucosamine (GlcNAc) of the core structure; or b) 1-3 linkage to branching N-
acetylglucosamines of GlcNAc1-4Man3GlcNAc2 (Figure 2.10). The latter modification is part of 
the terminal “capping” or “decorating” reactions1 to branches. 
 
Figure 2.10 Typical complex N-glycan structures found on mature glycoproteins (Adapted from 
Essentials of Glycobiology, 2
nd
 edition) 
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 Other “capping” and “decorating” reactions that are not mentioned in the main text include addition of 
N-acetylgalactosamine (GalNAc) (yellow square) to branching galactose or N-acetylglucosamine 




The Lewis blood group
1
 antigens are a related set of glycans that carry α1–3 or α1–4 fucose 
residues, resulted from fucosylation on polyLacNAc chains (discussed later in this section). 













 epitopes can be shown below (Figure 2.11).  
 
Figure 2.11 Structures of Lewis
a
 (left) and Lewis
b





Sialylation: Addition of sialic acids i.e N-acetylneuraminic acid (Neu5Ac) or N-
glycolylneuraminic acid (Neu5Gc) is one of the “capping” or “decorating” reactions following 
addition of 1-4 galactose to branching GlcNAc (Figure 2.10).  
 
Figure 2.12 Two main types of sialic acids found in mammals – Neu5Ac (left) and Neu5Gc (right) 
Sialic acids are terminating monosaccharide units typically found on branches of complex N-
glycans, O-glycans, and glycosphingolipids (gangliosides). There are two main types of sialic 
acids: N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc) (Figure 
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 The term Lewis has its name derived from the family who suffered from a red blood cell 




2.12). The main difference between Neu5Ac and Neu5Gc lies in the extra oxygen atom, in 
between carbon and hydrogen atoms (indicated by the red arrow in Figure 2.12). Neu5Ac, or 
NANA is sialic acid terminal sugar exclusive to human as a result of mutation in an enzyme 
that inserts oxygen atom into Neu5Ac to Neu5Gc (Lieberman, 2008). Neu5Gc is therefore 
absent in humans but not in other mammals. In therapeutic glycoproteins, animal-derived 
products used in culture media provide a metabolic source of Neu5Gc (Bardor et al., 2005). 
 
 1,3-galactosylation: Galα1-3Gal epitope is one that carries two consecutive galactose 
residues joined via an 1-3 linkage (Figure 2.13). It is immunogenic to human because of the 
presence of anti-Galα1–3Gal antibodies in human serum. The existence of “-Gal" epitope 
could be attributed to the use of non-human cell line that expresses 1-3 galactosyl transferase 
(Figure 2.13) to produce therapeutic products. 
 
Figure 2.13 Structure of “-Gal” epitope (right) (Essentials of Glycobiology, 2nd edition) 
As earlier mentioned, since humans have circulating antibodies against immunogenic glyco-
epitopes such as -Gal or Neu5Gc, a potential for antigen–antibody responses exists that could 





Elongation of LacNAc tandem repeats (-3Gal1-4GlcNAc1-) to form poly-N-
acetyllactosamine or polyLacNAc (Figure 2.14). Poly-N-acetyllactosamine biosynthesis is 
directed by the alternating actions of β1–4 galactosyltransferases and β1–3 N-
acetylglucosaminyltransferases to add galactose and N-acetylglucosamine (GlcNAc), 
respectively (Figure 2.14). PolyLacNAc chains serve as acceptors for subsequent 
glycosylations, including fucosylation and sialylation. The linear nature and hydrophilic 
character allows it to be extended and serve as scaffolds presenting specific terminal glycans 
for recognition by mammalian galectins. 
 
Figure 2.14 Elongation of branch N-acetylglucosamine residues of N-glycans (Adapted from 




2.3.4 Roles of N-glycans in protein folding  
Besides the primary sequence, early N-glycan processing in the endoplasmic reticulum 
(ER) plays an important role in proper folding of membrane proteins and proteins destined to 
be secreted, and thus their three-dimensional protein conformation. Proper folding of 
glycoprotein involves formation of secondary structures like -helices and -strands, burying 




quaternary associations via oligomerization and multimerization. The ER lumen has a highly 
specialized environment for proper protein folding due to its oxidizing environment that 
promotes disulfide bond formation and reservoir of Ca
++
 required for binding activities of 
chaperones like calnexin (CNX) and calreticulin (CRT). These lectin-like chaperones 
recognize and bind to monoglucosylated forms of the N-glycan i.e. Glc1Man9GlcNAc2 on 
glycoprotein backbone to ensure correct protein folding prior to exit from ER.  
In mammals, N-glycan precursors i.e. Glc3Man9GlcNAc2-P-P-Dol, are added to the potential 
N-glycosylation sites of an incompletely folded protein backbone. The non-charged, bulky and 
hydrophilic nature of N-glycan precursors keep the glycoproteins soluble during folding while 
modulating protein conformation by forcing amino acids near the N-glycan precursors into a 
hydrophilic environment. Meanwhile, two glucose sugar units are removed by α-glucosidases I 
and II to yield Glc1Man9GlcNAc2, where it is then bound to CNX/CRT complex. Other 
chaperones
1
, on the other hand, bind to hydrophobic patches exposed on misfolded proteins 
and maintain their solubility as the proteins acquire their final conformation. In addition, 
enzymes such as protein disulfide isomerases (PDI) and endoplasmic reticulum proteins 
ERp59, ERp72 and ERp57 promote proline cis–trans isomerization and protein disulfide bond 
formation that are essential to proper protein folding. Therefore, a difference in N-
glycosylation between two proteins in ER could result in a different protein conformation en 
route to Golgi thus causing further differences in the late processing or maturation of N-
glycans such as fucosylation, sialylation etc. 
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2.4 Roles of N-glycans in therapeutic proteins 
2.4.1 Glycans in Biotechnology and the Pharmaceutical Industry 





 based on rational design, to recombinant glycoproteins
3
 because they can 
have important effects on biosynthesis, biologicial activities, and therapeutic efficacy of the 
glycoproteins (Bertozzi et al., 2009; Hossler et al., 2009). Glycobiology and carbohydrate 
chemistry have become increasingly important in modern biotechnology. In 1996, US Food 
and Drug Administration (FDA) requires for patent application that the glycoform profile of a 
therapeutic glycoprotein be extensively characterized. Glycoproteins, which include 
monoclonal antibodies, enzymes, and hormones, are fast growing in the biotechnology 
industry, with sales exceeding billions of dollars annually.(Varki and Sharon, 2009).  
 
2.4.2 Therapeutic glycoproteins 
2.4.2.1 Sialylated glycans improve circulating half-life of Erythropoietin (EPO) 
Erythropoietin (EPO) is perhaps the most successful biotechnology therapeutics to 
date. It is a cytokine that circulates and binds to the erythropoietin receptor, inducing 
proliferation and differentiation of erythroid progenitors in the bone marrow thereby 
promoting erythropoiesis – red blood cell production. As a therapeutic, it is used to treat 
anaemia caused by lack of erythropoietin or by bone marrow suppression
4
. 
EPO is a recombinant glycoprotein that carries three sialylated complex N-glycans and 
one sialylated O-glycan. Though only marginal difference in activity is observed for 
glycosylated and deglycosylated EPO in vitro, glycosylation is crucial for the circulating half-
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 Natural products that possess glycan structures are antibiotics such as streptomycin, erythromycin A, 
chemotherapeutic drug such as doxorubicin, and digoxin used in cardiovascular disease 
2






 Glycoproteins are monoclonal antibodies, hormone, enzymes etc. 
4





life of EPO. It is found that the activity of deglycosylated EPO reduced by about 90% as they 
are rapidly cleared from the body before EPO can act on the receptors (Cummings and 
McEver, 2009). To reduce the rapid clearance effect for EPO, one can do so by having fully 
sialylated N-glycan chains; by increasing the amount of tetra-antennary branching
1
; by 
deliberately adding a N-glycosylation site; and by covalently linking polyethylene glycol 
(PEG) to the glycoprotein. 
2.4.2.2 Effector functions of immunoglobulin (Ig) Fc is glycan-dependant 
 
Figure 2.15 The -carbon structure of the immunoglobulin (Ig) G (Adapted from Jefferis 2009) 
 
While an immunoglobulin uses its Fab to bind and recognize surface antigens on target, 
it relies on Fc domains to activate the complement and effector functions
2
. To activate the 
effector functions, Fc of immunoglobulins bind to limited set of effector molecules and Fc 
receptors of natural killer cells, neutrophils and eosinophils (Siberil et al., 2007; Nimmerjahn 
and Ravetch, 2008) that trigger inflammatory response and antigen elimination via mechanism 
such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent 
cytotoxicity (CDC) (Raju, 2008; Chan and Carter, 2010).  
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 These approaches increase activity of EPO by nearly ten-fold 
2
 Complement system is a process of marking the antigen bearing targets and ingestion by phagocytes, 
which is also called opsonisation; effector function is triggered when Fc receptors of NK cells 




The primary amino acid sequences of different Fc domains
1
 play the primary role in 
effector functions in general. Recent studies have shown that Fc glycosylation of glycoproteins 
are also essential for the activation of effector functions and complement necessary for ADCC 
(Burton and Dwek, 2006; Kaneko et al., 2006; Anthony et al., 2008). In particular, the impact 
of Fc glycosylation on antibody structure and therefore therapeutic efficacy is also evident 
(Mimura et al., 2000; Ha et al., 2011). In another study, the removal of the fucose from N-
glycan core structure attached to the Fc domains of IgG has also been shown to dramatically 
enhance the effector functions (Shibata-Koyama et al., 2009). Besides immunoglobulin G, 
effect of N-glycosylation to the conformation of immunoglobulin M (IgM) has also been 
reported (Wormald et al., 1991). Abnormality of glycosylation at Asn-402 due to amino acid 
exchange at position 406
2
, on the heavy  chain of IgM has shown to cause defect in 
complement-dependant cytolysis. It was believed that the point mutation causes a 
conformation change of C3 domain folding that affects glycosylation at the Asn-402 (Wright 
et al., 1990). 
Hence, it is believed that N-glycosylation has a role to play in protein conformation 
and also biological functions of an antibody that would allow strategic optimization of 
glycosylation of therapeutic glycoprotein to achieve maximum efficacy (Jefferis, 2009; Jiang 
et al., 2011). 
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 Different Fc portions give rise to different classes or subclasses of immunoglobulin (Ig). Examples of 
subclasses for IgG are IgG1, IgG2, IgG3 and IgG4 
2




2.5 Characterization of immunoglobulins (Ig) 
2.5.1 Glycomics 
Glycomics, which belongs to one of the “omics” science1, is the systematic and 
methodological elucidation of the glycome
2
, the complete spectrum of glycans and their 
biological relationship in a given cell type or organism. Compared to the genome or proteome, 
elucidating the glycome of a cell type is no less than a daunting task, simply because of the 
vast structural diversity in glycans –heterogeneity of glycosylation sites and glycan linkages; 
heterogeneity across different dynamic changes
3
; and of intraspecies and interspecies. 
Therefore, such extensive works require collaborative efforts like the Consortium for 
Functional Glycomics (CFG), which allows selected participating investigators to contribute 
and reveal structures, functions of glycans and glycan-binding proteins (GBPs) that have 
impact on human health and diseases. Within CFG, comprehensive databases on glycan array 
screening, glycogene microarray screening, mouse phenotyping, and glycan profiling are 
available on http://www.functionalglycomics.org.  
Diversity of glycans has proven to be vital in almost every biological activity, from 
intracellular signalling to organ development and tumor growth. Glycomics complements other 
“omics” sciences in providing a better picture of the physiology of a cell or organism. Despite 
its importance, progress in glycomics has always lagged behind that of proteomics and 
genomics
4
 until the 1980s, when the development of new technologies for exploring the 
structures and functions of glycans became available. 
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2.5.2 Characterization of glycosylated immunoglobuins 
2.5.2.1 Detection of glycosylated proteins 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) separates 
proteins based on size. Glycosylated proteins usually show one or more diffuse bands due to 
heterogeneity in the glycans. One could further investigate the presence of N-glycans by 
treating the glycoproteins with endoglycosidases such as peptide N-glycosidase F (PNGase F) 
or A (PNGase A). The result of such treatment is a change in mobility of protein bands such as 
collapse of diffuse bands or reduced molecular weight due to release of glycans from the 
protein backbone. The common detection methods for SDS-PAGE gels are performed using 
silver-staining (www.invitrogen.com) or coomassie blue staining depending on the amount of 
protein available and the level of sensitivity required. 
2.5.2.2 Detection of terminal glycan structures or glyco-epitopes 
Lectins are sugar binding proteins that are specific to terminal fucose, galactose, N-
acetylgalactosamine and terminal sugars such as 2,6-linked sialic acid. Usually, lectins are 
used as primary antibodies in Western blot to detect the presence of specific glycan types. One 
example of a commercially available lectin is concanavalin A that binds to non-reducing 
terminal -D-mannosyl and -D-glucosyl groups (Goldstein and Poretz 1986).  
Besides lectins, there are other antibodies that are specific to certain glyco-epitopes 
such as -Gal, Neu5Gc or Lewisa that can be used to detect their presence on proteins, 
especially immunoglobulins. Other methods such as radiolabelling and metabolic labelling are 
also used to detect the presence of glycans on glycoproteins (Mulloy et al., 2009). 
2.5.2.3 Detection of glycoforms  
Micellar electrokinetic chromatography (MEKC) is a technique that is used for 
evaluation of the percentage of site-occupancy analysis or fractionation and profiling of 
different glycoforms of immunoglobulins (James et al., 1994; Hooker and James, 2000). In 




to the protein. In other words, the M number of N-glycosylation sites of a glycosylated protein 
may be occupied at varying degree thus generating the possibility of M+1 peaks including one 
that has no site being occupied at all.  
 
 
2.5.3 Characterization of N-glycans  
2.5.3.1 Release and fractionation of N-glycans 
The release of N-glycans is often performed using enzymatic digestion by 
endoglycosidases. Peptide-N glycosidase F or PNGase F is mostly used (Tarentino and 
Plummer, 1994), because it cleaves all N-linked glycans except those with fucose attached to 
1-3 of the proximal GlcNAc (Tretter et al., 1991). Such fucose linkage is usually present in 
plant-produced glycoprotein and it can be cleaved using PNGase A instead. Released N-
glycans are then purified by chromatography followed by either fluorescent labelling or  
permethylation to increase sensitivity towards ionization. Then, labelled or permethylated N-
glycan preparations are cleaned and desalted before being analyzed using mass spectrometry 
(MS), which will be discussed in Section 3.2.2.5.  
Depending on the conformation of the glycoprotein, N-glycans may sometimes be 
hidden in the core structure and therefore be inaccessible to the digestive action of 
endoglycosidases. In such cases, glycoproteins are trypsinized
1
 to yield peptides and 
glycopeptides with N-glycans that are accessible to endoglycosidases. Instead of 
endoglycosidase treatment, peptides and glycopeptides resulting from trypsinization can also 
be injected into a liquid chromatochraphy (LC) column followed by MS analysis to obtain site-
specific information of N-glycans (Sumer-Bayraktar et al., 2011). Besides using trypsin, it has 
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been reported that chemical cleavage methods like cyanogen bromide
1
 and mercaptan-induced 
fragmentation were used to elucidate the site-occupancy of multiple N-glycan sites present in 
murine IgM (Anderson and Grimes, 1982).  
2.5.3.2 Profiling of released N-glycans using Mass Spectrometry (MS) 
Mass spectrometry (MS) is an analytical technique that ionizes and separates the 
resulting charged particles according to their mass-to-charge ratio (m/z). Mass spectrometry is 
well-known for its high sensitivity in detecting a wide range of masses and thus allows user to 
obtain the entire N-glycan profile of a glycoprotein. Information that can be obtained from 
mass spectrometry includes molecular mass, composition, sequence or branching of a glycan 
or glycopeptide chain. An MS instrument typically consists of a vaporization/ionization unit, 
an analyzer, and a detector. There are three types of vaporization/ionization units which are as 
follows: 
1. Fast atom bombardment (FAB); 
2. Matrix-assisted laser desorption/ionization (MALDI); 
3. Electrospray ionization (ESI).  
These three technologies allow direct ionization of non-volatile intact glycans, 
peptides and glycopeptides fragments.  
In FAB-MS, samples are dissolved in a liquid matrix and ionization/desorption is 
effected by a high-energy beam of particles fired from an atom or ion gun. High field magnets 
are the most powerful analyzers for this type of mass spectrometry. The strong ionisation 
nature of FAB-MS that generates unnecessary in source fragment ions, makes it unsuitable for 
analysis of biological compounds as intact molecules. As a result, ESI-MS and MALDI-MS, 
soft ionization methods which do not induce in source ion fragmentation, are more popular in 
the analysis of N-glycans on biological compounds.  
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In MALDI-MS, glycan samples and matrix are spotted, and air-dried to form crystals 
on the surface of a metal target. Matrix molecules, such as 2,5-dihydroxy benzoic acid (DHB), 
absorb energy from laser pulses and assist the energy transfer and ionization of glycan or 
glycopeptide samples. Ionized molecules would then travel through a time-of-flight (TOF) 
analyzer, where samples are separated according to the m/z ratio i.e. those with lower m/z 
would travel faster through the analyzer than those with higher m/z. MALDI-TOF itself does 
not generate in source fragments like FAB-MS does. This shortcoming is usually overcome by 
using two analyzers in tandem i.e. MALDI-TOF-TOF (MS/MS) for structural analysis which 
will be discussed in Section 2.5.4. However, MALDI-TOF has the advantage of being highly 
sensitive and able to produce singly charged ions. 
In ESI-MS, a stream of liquid containing the samples is stripped of solvent as it enters 
the ionization chamber, producing multiply charged particles. ESI-MS experiments are often 
performed in tandem with a quadrupole analyzer, and/or micro- or nanobore liquid 
chromatography (LC) permitting on-line chromatographic separation and mass spectrometry of 
different glycopeptides for example (LC/ESI-MS) (Morelle and Michalski, 2007). 
2.5.3.3 Sialic acid profiling of N-glycans 
Released N-glycans can be fractionated based on sialic acid content using HPAEC-
PAD
 
(High pH anionic exchange chromatography with pulsed amperometric detection). Sialic 
acids are negatively charged terminal sugar entities due to the presence of carboxylic acid 
(COO
-
) groups within the structures. Under high pH conditions and anionic exchange column, 
more sialylated N-glycans are more strongly retained by the stationary phase than those that 
are less or non-sialylated. This results in a separation profile based on the sialic acid content of 
the released N-glycans. Besides total sialic acid distribution, a high-throughput method to 






2.5.4 Structural analysis of N-glycans 
Mass spectrometry (MS) generates spectra of mass ions that must be substantiated by 
the glycan database associated with the host cell producing that glycoprotein. However, in 
certain cases, more than one glycan structure can be attributed to a specific mass peak, which 
requires further analysis to confirm the claim of one specific structure to that peak. There are 
several ways to do so, e.g. by MS/MS, NMR or exoglycosidase digestion.  
In MALDI-TOF-TOF (MS/MS), selected intact masses from the first analyzer are 
subjected to collision in an environment filled with inert gases such as air, helium (He), argon 
(Ar) in the chamber between two TOF analyzers and therefore fragmented. The generated 
profile of fragmented masses associated to the selected mass peak would provide information 
on the sequence, linkage or branching information of a glycan chain. Analyzing the profile of 
mass peaks by MALDI-TOF-TOF (MS/MS) or MALDI-TOF (MS) can either be performed 
using certain commercially available SimGlycan® software which analyzes the mass spectrum 
of MS/MS and provides suggested structures with different scores and ranks (discussed later), 
or manually through mass differences of consecutive mass peaks which will be discussed in 
Section 4.2.2. 
Nuclear magnetic resonance (NMR) spectroscopy, on the other hand, can provide 
anomericity, sequence and linkages of a particular monosaccharide residue in a glycan using 
1
H-NMR but also requires large quantities of materials, i.e. typically at least one milligram. 
Furthermore, removal of specific sugars by exoglycosidases such as sialidase or b-
galactosidase, from the terminal ends of glycans may result in a mobility change depending on 
the residues removed. Sometimes, glycans that are subjected to actions of these enzymes may 
also be reanalyzed using mass spectra by looking at the shift of certain mass peaks to 





2.6 Comparative modeling of protein 3D structures 
Protein 3-dimensional (3D) structures can provide insights into many biochemical 
functions at a near atomic-level resolution. However, the high costs involved and immense 
efforts required to experimentally determine protein structures limits the use of such approach. 
Computational prediction of protein structures provides a low-cost alternative to obtain such 
structures. Comparative modeling is a template-based approach to predict the 3D structure of a 
target protein, primarily based on its sequence similarity to existing homologous protein 
structures. Though comparative modeling is predictive in nature, it is the most accurate 
computational method to date. In fact, a model structure can be quite close to that of a real 
protein if its sequence similarity is relatively high between them.  
One reason for the viability of computational protein structure prediction techniques is 
that protein structures are more dependent on their amino acid sequences and less on the 
species that produces them (Bajaj and Blundell, 1984; Chothia and Lesk, 1986; Chothia and 
Lesk, 1987). It has been recently reported that there are about 78,477 protein structures 
deposited on the Protein Data Bank (PDB) as of today when this thesis was written, and 
automatic prediction has generated approximately 1.9 million models that have not been 
determined experimentally (Liu et al., 2011).  
For comparative modeling, sequence identity between the target protein and its 
template can be as low as 30% for relatively reliable structures to be predicted (Ginalski, 
2006). Below this level, one could resort to fold recognition algorithms i.e. piecewise assembly 
of smaller peptides to model a protein structure from a target sequence. Comparative 
modeling, or homology modeling, requires a full template protein structure to be present and 
identified. Fold recognition techniques, on the other hand, does not require the full template, 
and thus has broader applicability especially for uncharacterized proteins with no existing 
templates in PDB. There are two algorithms for fold recognition: ab initio and de novo 
methods. Ab initio methods only rely on physicochemical principles for atom simulation, 




approximately 1,400 unique folds in the current Structural Classification of Proteins (SCOP) 
database (Andreeva et al., 2008).  
To augment the existing PDB and SCOP databases, structural genomics initiatives 
(SGIs) have been launched to explore different regions of protein structural space by selecting 
targets from novel, structurally uncharacterized protein families (Chandonia and Brenner, 
2006). To date, these initiatives have added 9,600 new structures to PDB. 
 
2.6.1 Methods for comparative modeling 
Comparative modeling is best viewed as a strategy, rather than a single technique, for 
assembling information from various component methods (including assembly and associative 
techniques) toward a 3D structure prediction (Lushington, 2008). A flowchart of comparative 
modeling is shown (Figure 2.16), which comprises four sequential steps that are shown as 
follows. 
1. Fold recognition and template identification  
2. Target-template sequence alignment  
3. Model building and refinement 





Figure 2.16 Flowchart of comparative modeling method (Liu et al. 2011) 
2.6.1.1 Fold recognition and template identification 
The first step of the comparative modeling strategy involves the identification of 
template protein structures. These structures can be obtained from PDB database (Berman et 
al., 2007). Other databases such as SCOP (Andreeva et al., 2008), DALI
1
 (Holm and Sander, 
1998), and CATH
2
 (Cuff et al., 2009), can be used to narrow the search. To detect homologous 
protein structures from databases, searching algorithms such as BLAST (Altschul et al., 1990) 
and FASTA (Pearson, 1990) based on pairwise sequence comparison of target and template 
sequence, are used. In cases when sequence identity is low, PSI-BLAST (Altschul et al., 1997) 
algorithm can be used to improve the detection of homologous protein sequences for a specific 
target protein sequence. Besides BLAST, FASTA and PSI-BLAST, other profile-based 
algorithms, which were believed to perform better in the implementation of alignment 
procedure have also been described (Liu et al., 2011).  
Generally, BLAST search within the databases will return more than one suggested 
template structures that are sorted in order of their bits scores (highest first) and expectation 
values or E-values generated by the algorithms. Bits score indicates the quality of the best 
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alignment between target sequence and found template; whereas E-value tells of the biological 
significance of the search result, and the likelihood of common ancestry between target and 
template. Selection of which template to use for model building depends on what the final 
model is used for - whether it is for the study of protein-protein/ligand interactions, or 
conformation of target’s active-site. Templates that contain similar types of interactions as the 
target are important if it is for interaction study, whereas in the case of the conformation study, 
high resolution template i.e. one with highest bit score, is more desirable. In addition, to 
improve the quality of final predicted structure, use of multiple templates has also been 
attempted (Larsson et al., 2008).  
2.6.1.2 Target-template sequence alignment 
After the templates are found, they must be aligned to the target protein sequence. 
Standard sequence alignment methods used are Needleman-Wunsch (Needleman and Wunsch, 
1970) and Smith-Waterman (Smith and Waterman, 1981). These methods are based on 
dynamic programming algorithms that calculate scoring matrices such as BLOSUM (Henikoff 
and Henikoff, 1992) and PAM (Dayhoff et al. 1978). If sequence identity between target and 
template is high, these methods produce similar alignment; however, if sequence identity is 
low (usually less than 40%), multiple sequence alignment of homologous proteins has been 
used to improve alignment results (Jones et al., 1999; Rychlewski et al., 2000; Marsden et al., 
2002; Capriotti et al., 2004). Upon alignment, the molecular model can then be constructed. 
2.6.1.3 Model building and refinement 
There are three main approaches towards model building – rigid body assembly 
(Sutcliffe et al., 1987), segment matching (Levitt, 1992) and satisfaction of spatial restraints 
(Sali and Blundell, 1993). In rigid body assembly, atomic coordinates of the conserved regions 
are used to construct the main chain of conserved residues, core of the target protein, where 
loops
1
 and side chain atoms that fit the core protein conformation are added. On the other 
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hand, segment matching uses 100 six-residue peptides that account for 76% of protein 
conformational space to build the target core using C atoms from conserved residues (Unger 
et al., 1989). Lastly, satisfaction of spatial restraints uses the similarity of structural features of 
conserved residues to build 3D model subjected to restraints such as generic stereochemistry 
from molecular mechanics force fields, distance and angles between equivalent residues based 
on entire target-template alignment. Finally, an optimization is performed to search for global 
low energy conformations that minimize the restraint violations. 
The most difficult tasks during model building are the prediction of loop regions and 
side-chain conformations, which are often performed by tedious methods and protocols
1
 via 
trial-and-error. Model refinement, on the other hand, is done using molecular dynamics (MD) 
techniques. With the improvement in automated tools, the accuracy of the model built 
automatically is comparable to manually curated multiple template models (Venclovas and 
Margelevicius, 2009). 
2.6.1.4 Model evaluation/validation 
The final step in comparative modeling is the evaluation or validation of predicted 3D 
model structures. Algorithms that can be used to perform such task include PROCHECK, 
AQUA, SFCHECK, Squid, Molprobity (Oldfield, 1992; Laskowski et al., 1996; Vaguine et al., 
1999; Chen et al., 2010). These algorithms check the stereochemical properties
2
 of the 
predicted model structures to access their reliability. 
There is also another class of programs that evaluates the predicted model structures 
based on statistical potential mean force, of which its theoretical basis is highly debated 
(Finkelstein et al., 1995; Rooman and Wodak, 1995; Thomas and Dill, 1996).  
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Other algorithms using structure-bases scoring functions and physics-based energy 
functions have also been used to perform model assessment (Benkert et al., 2008; Benkert et 





3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Purified IgM 84 and 85 
mAb 84 and 85 are monoclonal antibodies, or immunoglobulin (Ig) M produced by 
mouse hybridoma clones, which in this thesis are referred to as IgM 84 and 85, respectively. 
They were generated by the Stem Cell group at Bioprocessing Technology Institute (BTI) as 
previously described (Choo et al., 2008). The clones of mAb 84 and 85 were first adapted and 
cultured in protein-free media by the Animal Cell Technology group at BTI in 5L bioreactor. 
Cell culture supernatants of mAb 84 and 85 were then clarified, captured and purified in two 
steps
1
 by the Downstream Processing group at BTI to achieve product purity above 95% in 
final storage buffer of 30mM sodium phosphate, 100mM NaCl, 5mM EDTA, 0.05% Tween 80 
and 73mM or 2.5% trehalose pH 7.5 (Tscheliessnig et al., 2009).  
 
3.2 Methods 
3.2.1 Construction of mouse N-glycans library 
Using Glycan Profiling database from Consortium for Functional Glycomics (CFG), 
mouse N-glycans library was constructed. The coverage of this library includes all cell types 
and spleen tissues of mouse species from various participating investigator as listed under 
Appendix C. All the structures are drawn using GlycoWorkbench software and saved as  
.gws file for analysis of mass spectra for N-glycan profiling of IgM 84 and 85.  
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3.2.2 Release and Fractionation of free N-glycans from IgM 84 & 85 
3.2.2.1 Fragmentation of IgM 84 and 85 
Fragmentation of IgM 84 and 85 was performed using Pierce® IgM Fragmentation 
Kit. To do so, 400g of purified IgM 84 (or approx. 174l of 2.3 mg/mL) and 85 (or approx. 
191l of 2.1 mg/mL) were first buffer-exchanged into digestion buffer (50mM Tris, 150mM 
NaCl, 10mM CaCl2, 0.05% NaN3 pH 8.0) that is provided in the kit, 3 times using centrifugal 
concentrators (10,000 MWCO, Amicon Ultra, Millipore) and final concentration was adjusted 
to 1.0 mg/mL assuming no loss of samples during this step. Samples of IgM were loaded onto 
immobilized typsin column at 60
0
C for 40mins before fragments of IgM were eluted and 
collected in fractions. Details of this method, which is also known as hot trypsin digestion 
(HTD) in the kit, can be found in the datasheet of Pierce® IgM Fragmentation Kit (Thermo 
Scientific). Two major fragments for IgM of mouse origins, as suggested by the protocol, are 
believed to be F(ab’)2 (150kDa) and “IgG” type-M (200kDa) (Figure 3.1).  
 
Figure 3.1 IgM fragments generated using trypsin (Adapated from Pierce® IgM Fragmentation 




3.2.2.2 Trypsin digestion of IgM 84 and 85 
Eluted fractions containing fragments of IgM84 and IgM85 were pooled, and equal 
volume of trypsin digestion buffer (50mM NH4HCO3, pH 8.2) was added to each pool of IgM 
sample. These samples were then further digested by adding 400l of 0.2g/l Sequencing 
Grade Modified Trypsin (Promega), which had previously been reconstituted in 1mM HCl 
solution, and incubated at 37
0
C with end-over-end mixing overnight. The same amount or 
volume of trypsin was added to each sample after 24 hours, and incubated once again at 37
0
C 
for a total of 48 hours to ensure complete digestion. This step was verified using SDS-PAGE 
technique, similar to that was described in Section 3.2.5.2. (Data not shown) 
Finally, N-Glycanase® (GKE-5006B, Prozyme) or Peptide-N-Glycosidase F (PNGase 
F) was diluted 25 times in N-Glycanase Reaction Buffer (100mM sodium phosphate, 0.1% 
NaN3, pH 7.5) before adding 100ul of 100mU/ml PNGase F into the mixture of completely 
digested IgM. Resultant mixtures were incubated overnight at 37
o
C. PNGase F from Prozyme 
cleaves all asparagine-linked complex, hybrid and high mannose oligosaccharides. 
3.2.2.3 Reversed-phase capture of free N-glycans using Hypercarb column  
Hypercarb SPE cartridges (200mg sorbent bed weight, Thermo Scientific) were used to 
capture free N-glycans from pool of digested mixture of peptides, enzymes and etc. Cartridges 
were pre-washed sequentially in the following order: 1CV
1
 of 1M filtered NaOH, 2CVs of 
water
2
, 1CV of 30% acetic acid (v/v), 1CV of water, 1CV of 50% ACN/0.1% TFA (v/v), and 
2CVs of 5% ACN/0.1%TFA (v/v) and 2CVs of water. Prior to sample loading, half the 
volume of each sample was kept for HPAEC-PAD in Section 3.2.4.2, which will be discussed 
later. 
After sample loading, each sample vial was washed thoroughly with 2mL of water, 
and the washes were also loaded onto the cartridge. This step is repeated three times to allow 
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for maximum product recovery. Each cartridge was washed with 3mL of water, followed by 
3mL of 5% ACN/0.1% TFA (v/v) before free N-glycans were eluted stepwise with 
50%ACN/0.1%TFA (v/v) i.e. 500L of elution buffer was loaded onto each cartridge to reach 
a final total volume fraction of 2mL.  
All eluted samples were collected in different glass vials, and then dried under 
constant blowing of N2 gas at room temperature until the entire elution buffer vaporized.  
3.2.2.4 Permethylation 
Four sodium hydroxide (NaOH) pellets (Merck) were ground in approx. 3mL of dry 
dimethyl sulfoxide (DMSO) (Merck) that had been added into a dry mortar to form slurry. 
About 0.6mL of the resulting DMSO/NaOH slurry was added into the glass vial containing 
dried samples, followed by 1.0mL
1
 of iodomethane (Merck) to arrive at a volumetric ratio of 
approx. 2:1. Note that iodomethane should be added sufficiently to avoid under-
permethylation. Reaction mixture was then left to react at room temperature for at least 1 hour 
under constant end-over-end mixing. At the end of reaction, water was added dropwise to the 
reaction mixture to quench any excess iodomethane. 
To extract permethylated samples from aqueous phase, approximately 1-2 ml of 
chloroform (CHCl3) (Merck) or organic phase was added. The resulting two-phase solution 
was vigorously mixed and allowed to settle under gravity. Aqueous phase, which would settle 
on top of organic phase, was aspirated under vacuum. Following this extraction step, organic 
phase (which now contains the sample) was washed 5-8 times before they were dried under 
constant blowing of N2 gas at room temperature until the entire organic phase vaporized. 
Permethylation
2
 increases the hydrophobicity of free N-glycans. 
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3.2.2.5 Desalting step using Sep-Pak® column  
Sample in each glass vial was reconstituted in 200ul of 50% methanol (v/v) aqueous 
solution. Sep-Pak cartridges (C18, 200mg sorbent bed weight, Waters) were pre-conditioned in 
the following order: 5mL of 100% methanol, 5mL of water, 5mL of 100% ACN and finally 
5mL of water prior to sample loading. Upon sample loading, glass vials were washed with 
2mL of water and loaded onto the respective cartridges to allow maximum product recovery. 
Cartridge was washed with 5mL of water to dissociate any potential non-specific binding, and 
also serve as a clean-up or desalting step. Finally, bounded permethylated N-glycans were 
eluted in four fractions - 15% ACN, 35% ACN, 50% ACN and 75% ACN aqueous solution. 
Similar to previous elution steps done in Hypercarb cartridge, each fraction was eluted in four 
steps i.e. 0.5mL x4 to arrive at a final total volume of 2mL. Eluted samples were freeze-dried 
before they were characterized by MALDI-TOF mass spectrometry (MS).  
3.2.2.6 MALDI-TOF MS 
MALDI-TOF MS stands for matrix-assisted laser desorption/ionization (MALDI) 
time-of-flight (TOF) mass spectrometry (MS). It is one of the three most commonly used mass 
spectrometry methods to characterize oligosaccharides, peptides or glycopeptides in 
glycobiology. In our case, permethylated N-glycans from IgM 84 and 85 were reconstituted in 
30ul of 80% methanol (v/v). Tubes were thoroughly vortexed to ensure all N-glycans dissolve 
in the aqueous solution. 0.5ul of sample solution was spotted on a MALDI plate, specially 
designed for Applied Biosystems 4800 Plus MALDI-TOF/TOF (Applied Biosystems), 
followed by 0.5ul of 2,5-dihydrobenzoic acid (DHB) matrix solution. Additional 0.5ul of 
100% ACN was spotted on top of the sample and matrix solutions to allow sample 
crystallization to take place. To use the Applied Biosystems 4800 Plus for MALDI-TOF MS, 
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Selected mass peaks of IgM 84 and 85 samples that had been identified to have few 
suggested glycan structures were subjected for further fragmentation using MALDI-TOF-TOF 
or MS-MS. Fragmentation of selected ionized masses passing through collision-induced 
dissociation (CID) chamber were controlled 1) by increasing potential difference of across 
analyzers from 0, 1 or 2kV and 2) using heavier colliding inert gases such as argon (Ar) 
compared to air. Prior to CID fragmentation, CID was purged with inert gases. The accuracy 
of masses that are entered into preset MSMS Acquisition Methods were up to 2 decimal places.  
 
3.2.3 Site specific N-glycan profiling of IgM 84 & 85 
3.2.3.1 Reduction and alkylation of IgM 84 & 85 
Purified IgM 84 and 85 (100g) in storage buffer (as described in Section 3.1.1.) were 
denatured by adding appropriate volume of 8M guanidine hydrochloride (GdnHCl) in 0.3M 
Tris-HCl pH 8.4, such that the final concentration of GdnHCl is 6M. The resulting mixture 
was incubated at 37
o
C for 1 hour. Following denaturation, 1mM dithiothreitol (DTT) aqueous 
solution was added according to molar ratio of DTT: IgM = 300:1, before incubation at 37
o
C 
for 1 hour. After the previous reduction step, IgM samples were alkylated by adding 2.5mM 
iodoacetamide (IAA) according to molar ratio of IAA: DTT = 2:1. The final mixture was 
incubated at 37
o
C for 1 hour in the dark. After final incubation, the mixture was dialyzed twice 
for 3 hours in large quantity of water i.e. at least 1L using Pierce dialysis cassettes (10kDa 
MWCO, Thermo Scientific) before the samples were left overnight for dialysis at 4
o
C. 
3.2.3.2 In-gel trypsin digestion  
Reduced and alkylated samples of IgM 84 and 85 in water were loaded onto a  
4-12% Bis-Tris NuPAGE gel (Invitrogen) and run for 35 mins at 200V in 1X MES running 
buffer
1
. Gel was removed from the cassette housing and stained in Coomassie Blue for 5 mins 
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before destaining in 10% ethanol, 10% acetic acid for 10 mins in multiple intervals. The 
destaining buffer was continually changed until protein bands became visible. Protein bands of 
interest
1
 were excised and cut into smaller gel cubes with a sterile scalpel before transferring 
them into clean Eppendorf tubes. Gel cubes were washed with 200l 0.1M NH4HCO3/ACN 
(1:1 in volume) by vortexing and incubation under constant end-over-end mixing on a rotary 
shaker for 15 mins at room temperature. Supernatants of were removed and dried under 
vacuum. The washings and drying steps were repeated twice. Prior to in-gel trypsin digestion, 
all protein bands in gel cubes are reduced and alkylated again in by incubation in the dark in 
200l of 0.1M DTT (45 mins, 55oC) and 200l of 55mM IAA (30min, room temperature) 
solutions, respectively. After incubation, samples were cooled to room temperature before they 
were washed again with 0.1M NH4HCO3/ACN (1:1 in volume) before drying under vacuum 
for 3min. This washing and drying steps were repeated once only.  
Lypholized sequencing grade modified trypsin (Promega) was reconstituted in 100ul 
of water to form trypsin solution. 100ul of 20% trypsin solution in 0.1M NH4HCO3 (v/v) was 
added to each sample and incubated for 45 mins at 4
o
C before incubating samples at 37
o
C 
overnight. In the next day, gel cubes were washed in the following order: 100l of 100% 
ACN, 100l 0.1M NH4HCO3, 100l ACN and finally 100l 5% formic acid. All supernatants 
were recovered during all these washing steps, and transferred into a glass vial for 
lyophilisation. 
3.2.3.3 Fractionation of glycopeptides/peptides using Sep-Pak® column 
Lyophilised samples of IgM 84 and 85 glycopeptides and peptides were reconstituted 
in 200l of 50% methanol aqueous solution (v/v). Steps to pre-condition Sep-Pak® cartridges, 
sample loading and elution, were done according to those have been described in Section 
3.2.2.5,  except that fractions were eluted at 5 different ACN concentrations instead: 5%, 10%, 
15% and 20% ACN and 100% ACN (v/v) before drying.  
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 Protein bands of interest were determined by identifying their molecular weight using a molecular 




3.2.3.4 MALDI-TOF MS and MALDI-TOF-TOF (MS/MS) 
After drying, 30ul of 80%v/v methanol (v/v) was added to each sample before spotting 
them on MALDI metal plate with DHB matrix and ACN for crystallization of samples to take 
place. Detail steps were previously described in Section 3.2.2.6. One difference here was the 
use of -cyano-4-hydroxycinnamic acid (-Cyano) over DHB because of its ability to ionize 





 Software can be found under Table 3.1. For selected mass peaks that needed 
to be fragmented further, procedure was done according to that had been described in Section 
3.2.2.7 
3.2.3.5 Amino acid sequence analysis 
Full DNA sequencing for IgM 84 and 85 was performed by Stem Cell group and the 
respective primary amino acid sequences were then derived. We determined all the potential 
N-glycosylation sites on the heavy and light chains of IgM 84 and 85 besides analyzing the 
peptide and glycopeptides sequences from trypsin digestion, which was required to determine 
the site-specific N-glycosylation information of IgM 84 and 85. Only small segment of these 
sequences are shown in Appendix A due to confidentiality of information. 
Furthermore, sequence alignment was performed by Dr. Miranda Van Beers to 
determine the sequence similarities between the variable and constant regions of heavy and 
light chains of IgM 84 and 85 (Website: http://pir.georgetown.edu/). The sequence similarities 
results of different variable regions of IgM 84 and 85 were cross-compared with their 
respective 3D structural models that we generated in this thesis. 
 
3.2.4 Sialylation of IgM 84 & 85 
3.2.4.1 Sialic Acid (SA) quantification using high throughput method (HTM) 
The total amount of sialic acids on purified IgM 84, and IgM 85 was quantified by 




a calibration range, 1M sialic acid stock solution (Sigma Aldrich) was serially diluted to obtain 
standards at five different concentrations i.e. 0, 10, 20, 40 and 60M. On the other hand, IgM 
samples were diluted in storage buffer, as previously described in Section 3.1.1, to a 
concentration of 100g/ml.  
A volume of 30l of each standard or sample was diluted in 30l of 0.2M acetate 
buffer in 200l tubes (Axygen). 0.2M acetate buffer pH 5.0 was pre-adjusted with 1.21M HCl 
such that the resulting acetate buffer would give a pH 5.2 to the final mixture of 
samples/standards that is optimal for neuraminidase activities.For each sample tube, 2l of 
water, 1.25l of neuraminidase1 (5U/100l, Roche) and 3.75l of 50mM acetate buffer pH 5.2 
were added; whereas for each standard, 2l of water and 5l of 50mM acetate buffer pH 5.2 
were added without neuraminidase, and the resulting mixtures were incubated at 37
o
C for 5 
min. Following incubation, 90l of 0.15M borate buffer pH 9.4 was added to each tube, 
followed by 12l of in-house prepared malononitrile before the final mixtures were incubated 
at 80
o
C for 5 mins. Reaction was then stopped by incubating on ice for 1 min. Finally, 
mixtures were transferred to 96-well plate to measure fluorescence emission at a wavelength of 
430nm after excitation at 357nm.  
3.2.4.2 Relative percentage quantification of sialylated N-glycans using HPAEC-PAD 
Set of samples that were kept from Section 3.2.2.3, were spiked with 10ul of Raffinose 
before they were being loaded onto different set of pre-conditioned Hypercarb SPE cartridges 
(200mg, sorbent bed weight, Thermo Scientific). Pre-conditioning of the cartridges and sample 
elution were done as described in Section 3.2.2.3. HPAEC-PAD, which stands for high pH 
anionic exchange chromatography with pulsed amperometric detection, is used to fractionate 
the pool of sialylated N-glycans according to their differential surface charges. After drying, 
samples were reconstituted in 150l of water before a volume of 30l of each sample was 
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 Isolated from Clostridium perfringens, an acylneuraminyl hydrolase, EC 3.2.1.18; it cleaves terminal 
sialic acids linked via (2-3), (2-6), or (2-8), and it is supplied in lyophilized form and is 






 PA200 analytical column (3x250mm, Dionex) of the BioLC system 
(Dionex) at flow rate of 0.3ml/min. Mobile phases are 500mM acetic acid and 500mM NaOH 
with varying degree of mixing between 0 and 100%. 
3.2.4.3 Relative percentage quantification of sialic acid types using HPAEC-PAD 
There are two types of sialic acids i.e. Neu5Ac and Neu5Gc and the main difference 
between them is previously described in Section 2.3.3 and Figure 2.12. These two types of 
sialic acids were released from samples of IgM 84 and 85 using acidic treatment and incubated 
in 2M acetic acid for 3 hours at 80
o
C. Released Neu5Ac and Neu5Gc remain in the solution 
and were collected in the filtrate after spinning down using 10kDa MWCO centrifugal filters 
(Amicon
® 
Ultra, Millipore) at 14,000rpm for 20 min on a benchtop centrifuge (Beckman 
Coulter). Samples were then dried under vacuum and reconstituted in 150l of water before 
injecting samples onto the CarboPac
®
 PA20 analytical column (0.4x150mm, Dionex) of the 
BioLC system (Dionex) at flow rate of 0.5ml/min, mobile phases are 500mM acetic acid and 
500mM NaOH with varying degree of mixing between 0 and 100%.. Standards of Neu5Ac and 
Neu5Gc were also injected in separated runs to identify the elution times of these sialic acids 
in our samples.  
 
3.2.5 Gel electrophoresis and Western blot analysis of glyco-epitopes 
3.2.5.1 Protein extraction from mouse heart 
Mouse hearts were first harvested, followed by protein extraction using Novex® Tris-
Glycine Native Sample Buffer
1
 (2X concentrated, Invitrogen) diluted with water. Sufficient 
volume of tris-glycine native sample buffer (diluted to 1X) was used for sonication, which was 
performed intermittently to avoid excessive heat build-up during this process. Protein extracts 
were then spun down at 14,000 rpm for 20 mins using a benchtop microcentrifuge (Beckman 
Coulter) and supernatant was removed and used for gel loading in the next step. This sample is 
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used as the positive control for Western blot detection of gal (1,3) gal terminal epitope of N-
glycans released from IgM 84 and 85.  
3.2.5.2 SDS-PAGE Gel Electrophoresis 
IgM (between 0.5 – 2.0g) samples were pre-treated by adding LDS Sample Buffer1 
(4X concentrated, Invitrogen) and 500mM dithiothreitol (DTT) (10X concentrated, Invitrogen) 
at 70
0
C for 10 mins before loading onto a pre-cast gel of 4-12% Bis-Tris SDS-PAGE
2
 
(Invitrogen). The gel was run at 200V for 35 mins according to protocol by Invitrogen. 
However, to identify the J-chain of IgM 84 and 85, we reduced the run time to 30 mins due to 
its relatively smaller molecular weight i.e. approx. 20kDa of this IgM domain. 
3.2.5.3 Silver Staining  
Gels were removed from the plastic cassette and stained using reagents supplied by 
SilverQuest
TM
 Silver Staining Kit, according to the Basic Protocol as described under the 
instruction menu. More details can be found on website: www.invitrogen.com.  
3.2.5.4 Western Blot 
Protein samples were also transferred and detected using Western blot. To perform this 
experiment, gels were removed and transferred onto PVDF membrane using iBlot
TM
 
(Invitrogen) for 7 mins using iBlot® Gel Transfer Stacks PVDF. Depending on the epitopes or 
immunoglobulin chains, different primary, secondary antibodies and blocking agents were 
used as shown in Table 3.2. After blocking overnight at 4
0
C, the membrane blots were washed 
and incubated for 5 mins with Tris-buffered Saline (TBS), 0.1% Tween 20 or TBST (20mM 
Tris, 500mM NaCl, 1mM CaCl2, 0.1% Tween 20 pH 7.0) and this washing step was repeated 
four more times before incubation of primary antibodies. Again, the membranes were washed 
as described 5 more time before incubation of secondary antibodies, and another 5 times 
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 LDS stands for lithium dodecyl sulfate and the buffer composition for 4x LDS sample buffer – 10% 
Glycerol, 141mM Tris Base, 106mM Tris HCl, 2% LDS, 0.51mM EDTA, 0.22mM SERVA® Blue 
G250, 0.175mM Phenol Red, pH 8.5 
2
 Pre-cast gel is available off-the-shelf at different gradient and loading well; choice of gel used depends 
on number of samples and loading volume of sample has to be adjusted appropriately. More details can 




before adding detection agent. ECL Plus (GE Healthcare) was used as substrate for 
chemiluminescent detection of protein domains and different epitopes of N-glycans from IgM 
84 and 85 using X-ray film in the dark room.  
Table 3.2 Primary and secondary antibodies used in different western blots 
Target Blocking  Primary Secondary 
-Gal 




Goat anti-human IgG-HRP 
(Millipore) 
Neu5Gc 




Donkey anti-chicken IgY-HRP 
(Jackson ImmunoResearch) 
J-chain 
5% NFM1 in TBST (v/v) 
(Sialix) 
Anti mouse J-chain 
(Santa Cruz) 
Goat anti-rabbit IgG-HRP 
(Santa Cruz) 
 
3.2.6 Molecular weight and monomer fraction determination using SEC 
100ul of IgM 84 and 85 samples (concentration: 1mg/ml) were injected onto Tosoh TSK 
G4000 SWXL (7.8 mm x 30 cm) at 25
o
C on a High Performance Liquid Chromatography 
(HPLC) system (Shimadzu). Samples were run under constant flow rate of 0.6ml/min using 
0.2M sodium phosphate, 0.1M potassium sulfate buffer pH 6.0. Static Light Scattering (SLS) 
is used in tandem to UV280nm detector to measure molecular weight (MW) and hydrodynamic 
radius (rH ) of both IgM 84 and 85.  
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 BA stands for Blocking Agents, supplied by Sialix, Inc; NFM, on the other hand, stands for non-fat 




3.2.7 Mass spectrum analysis 
3.2.7.1 Data Explorer 
Mass spectrum data files were generated by AB SCIEX Voyager Instruments using 
MALDI-TOF MS or MALDI-TOF-TOF MS/MS. These data files were viewed in Data 
Explorer
®
 as shown in Figure 3.2. Every mass ion displayed on a mass spectrum shows a 









C. Each of these four peaks was separated from each other by 1Da.  
 
Figure 3.2 Section of mass spectrum generated by MALDI TOF MS was displayed. Y- and X-axes represent 
the intensity of mass ion and absolute mass (Da) respectively. Each of the two mass ions above display a 
distinct set of four peaks due to the presence of isotopes like 1H,  2H 12C and 13C with 1H and 12C being the 
most abundant species 
Besides identifying the presence of specific mass ion, Data explorer
®
 also provides us 
with information of absolute intensity of each individual peak. In identifying the absolute 
intensity of each mass peak, only the first or lowest mass peak was chosen but not necessarily 
the one with highest intensity (Figure 3.2). With absolute intensity, we then calculated the 
percentage relative abundance (%RA) of each mass ion as follows. 
    
                                       
                                         




Besides, we categorized all the peaks in four groups – high mannose, biantennary and 
triantennary complex type, and hybrid. With this, we also calculated the percentage 
distribution (%D) of individual mass ion within a group as follows. 
   
                                       
                                                    
      
The results of the %RA and %D were tabulated in Appendix D, as shown in Table D1 
and D2. However, prior to that, individual mass ion of interest need to be first identified by 
matching the masses of mass spectra with the theoretical masses of all N-glycans in mouse N-
glycan library, which can be constructed using GlycoWorkbench.  
 
3.2.7.2 GlycoWorkbench 
Mouse N-glycan profiling library was constructed using GlycoWorkbench software. 
Source for these N-glycan structures were obtained from the public domain - Functional 
Glycomics Gateway, led by Consortium for Functional Glycomic (CFG) 
(http://functionalglycomics.org). CFG is a large international initiative that enables 
Participating Investigators to share functions of glycans and glycan-binding proteins (GBPs) 
that impact human health and disease. At the same time, this also serves as a knowledge base 
to the scientific community where one can access to the latest findings and development in 
study of glycans.  
List of mass peaks that satisfy certain signal-to-noise ratio was exported from Data 
Explorer
®
 and used to match with the theoretical masses of corresponding N-glycan structures 
in the library. For masses that match multiple suggested structures, MALDI-TOF-TOF MS/MS 
that fragmented intact mass ion further was used to further elucidate the identity of mass ion. 






3.2.7.3 SimGlycan Enterprise Client 2.92 
SimGlycan
®
 predicts the structure of a glycan from MALDI-TOF-TOF MS/MS data. 
SimGlycan
®
 matches MS/MS data generated by mass spectrometry against its own database of 
theoretical fragmentation of over 8,000 glycans and generates a list of probable glycan 
structures. The SimGlycan
®
 has a robust database that consists of theoretical fragments of 
known glycan structures made up of 62 different monosaccharides. Every glycan in the 
database is fragmented for each of the possible fifty one reaction conditions using an intensive 
fragmentation algorithm. The extensive and comprehensive nature of this database ensure the 
high fidelity of the probable glycan structures.  
The search mechanism used in SimGlycan software is based on matching algorithm. It 
compares the experimentally determined fragment masses with a reference set of theoretical 
fragment masses.  
Composition score calculates how fully a suggested structure is supported by the 
experimental masses regardless of other suggested structures. Higher score is given to those 
candidate structures whose theoretical glycosidic fragment masses match maximum of the 
experimental mass. Composition score consists of the following percentage matches: 
a) % Glycosidic Match: percentage match of single glycosidic and glycosidic fragments 
against the experimental masses 
b) % Cross ring Match: percentage match of single cross ring and cross ring/glycosidic 
fragments against the experimental masses 
Branching Pattern score determines the degree of closeness of one suggested 
structure to the real glycan relative to other suggested structures. Higher score is given to the 
suggested structure whose theoretical mass fragments match those of experimental masses 
with higher intensity or relative abundance. This score is also based on a weighted scoring 




sequentially followed by average match cross ring intensity and average match overall 
intensity.  
Suggested structure with the highest composition score and highest branching pattern 
score was given the highest glycan rank, and therefore the most proximate structure for the 
unknown glycan subjected to MS/MS. The list of masses that were subjected for MALDI-





3.2.8 Discovery Studio – software for homology modeling  
Discovery studio is a comprehensive software suite for molecular modeling and drug 
discovery. We used this software to create 3D model structures for variable regions of IgM 84 
and 85 using homology modeling. In Discovery Studio, creating homology models from a 
protein sequence uses a number of protocols which can be summarized into the following four 
steps:  
Template identification: Potential templates that can be used for model construction 
can be identified using Sequence Analysis protocols such as BLAST Search (DS Server) or PSI-
BLAST Search. If the sequence identity of target sequence is between either 25%-60% or 
above 60%, BLAST can identify correct templates effectively. However, if the sequence 
identity is below 25%, iterative searching method (PSI-BLAST) can be used instead. There are 
two sequence databases, PDB and PDB_nr95 available. It is most common to search templates 
against the non-redundant sequence database PDB_nr95
1,2
.  
Scoring matrix used is BLOSUM62. BLAST then compares the homology between 
two sequences using the following equation (Eddy, 2004) 
       
 
 
   
   
    
 
where  
Pab = likelihood of test hypothesis, i.e. two residues a and b are correlated because they are 
homologous 
fa, fb = likehood of null hypothesis, i.e. two residues a and b are uncorrelated and unrelated, 
occurring independently 
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 nr95 = 95% non-redundancy 
2
 Two or more homologous proteins with sequence identities that are larger than 95% would be 




Aligning model sequence to templates: Align Sequence to Templates protocol aligns 
model sequence with selected templates based on structure similarities between the two. Better 
alignment can be obtained by creating a sequence profile and aligning the sequence profile to 
the pre-aligned structures. A good sequence profile is a sequence alignment that contains a 
large set of homologous, but non-redundant set of sequences.  
Building 3D model using MODELER: The Align Structures (MODELER) protocol 
creates model protein structures of a target sequence based on the target-template alignment. 
MODELER treats ligands of template as rigid bodies and they are copied to the model 
structures as BLOCK residues. Loops are segment of sequences on the model that can be 
further refined within the protocol itself. This protocol calculates and returns two scores - PDF 
Total Energy
1
 or Physical Energy
2
, and DOPE (Discrete Optimized Protein Energy) for each 
model that it builds for evaluating the quality of the models. A model is better optimized 
against the homology restraints when it has lower PDF Total Energy and models with the least 
violation to homology restraints are preferred. However, if the models all have similar PDF 
Total Energy, you can use the DOPE score which is based on statistical potential as a measure 
of the model quality i.e. the lower the score, the better the model.  
Assessing validity of the 3D structure: The Verify Protein (Profiles-3D) protocol allows 
you to evaluate the fitness of a protein sequence in its current 3D environment. It can be 
applied to assess the quality of a theoretical model or to examine the characteristics of an 
experimental structure. For example, it can be used to find hydrophobic patches on the surface 
of a structure. More hydrophobic patches on the surface of a protein, except for membrane 
proteins, would result in lower score as they tend to reside within the core in tertiary or 
quaternary structures. The protocol returns Verify Score
3
 for the protein, together with 
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 PDF stands for probability density function; PDF Total Energy is the sum of the scoring function value 
of all homology-derived pseudo-energy terms and stereochemical pseudo-energy terms 
2
 Sum of energies of the stereochemical pseudo-energy terms which consist of valence bonds, valence 
angles and torsion angles, improper torsion angles, and soft-sphere repulsion, as well as knowledge 
based non-bonded potentials used only for loop and mutant modeling 
3






 and Expected Low Score
2
. If the model structure has a Verify score 
higher than the expected high score, the structure is likely to be correct. If the overall quality 
score is between the reference values, then some or all of the structure may be incorrect, and it 
requires closer scrutiny. If the overall quality is lower than the expected low score, then the 
structure is almost certainly misfolded. 
Last but not least, using Align and Superimpose Proteins protocol, we also performed a 
structural superimposition of the 3D model structures for variable regions of IgM 84 and 85 
and calculated the root mean square difference (RMSD) to quantify their spatial differences. 
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 Statistical analysis of high-resolution structures in the Protein Data Bank (PDB) 
2




4 RESULTS AND DISCUSSION 
4.1 Characterization of protein IgM 84 and 85 
4.1.1 Physical properties of IgM 84 and 85 using SEC-HPLC/SLS 
 
Figure 4.1 SEC-HPLC UV280nm of IgM 84 and 85  
 
Size exclusion chromatography – high performance liquid chromatography (SEC-
HPLC) was used in tandem with static light scattering (SLS) detector to characterize a few 
physical properties of protein IgM 84 and 85 i.e. hydrodynamic radius (rH), molecular weight 
(MW) percentage population of IgM aggregates, pentamers and fragments. This analysis is 
particularly crucial to determine the quality of the purified IgM because presence of large 
amount of IgM aggregates may render glycosylation analysis more difficult to interpret and 
more complex during preparation steps mentioned in Chapter 3 thus affecting the quality of 
























 SEC separates protein molecules primarily on rH or size of protein, which in this case 
are IgM aggregates, pentamers and fragments. IgM aggregates, being the largest in size, were 
excluded from the pores of chromatographic column and therefore eluted first at 11.82 min ± 
0.12%
1
 (IgM 84) and 11.93 min ± 0.77% (IgM 85) (as indicated by red arrow in Figure 1); 
while IgM pentamers eluted at 13.40 min ± 0.00% (IgM 84) and 13.55 min (IgM 85) (as 
indicated by blue arrow in Figure 1). Fragments of IgM 84 and 85 were eluted close to but 
before the buffer/salt peaks (as indicated by green arrow Figure 4.1) at 20.33 min ± 0.00% and 
20.39 min ± 0.21%, respectively (as indicated by brown arrow Figure 4.1). Samples of purified 
IgM 84 and 85 in final storage buffer contained high percentage of IgM pentamers, and low 
levels of aggregates (Table 4.1). The percentages of IgM 84 and 85 fragments could not be 
reliably determined due to their closeness and/or overlapping with buffer/salt peak intensities 
(Figure 4.1). However, they account for not more than 1% of the total amount of IgM. Using 
Static Light Scattering (SLS), MW and rH of IgM 84 and 85 determined and they were found 
to be rather similar (Table 4.1). 
Table 4.1 Physical properties of IgM 84 and 85 determined using SEC-HPLC/SLS 
IgM  












IgM 84  1.30 ± 4.35%  97.83 ± 0.22%  889.00 ± 0.10%  14.05 ± 0.50%  
IgM 85  1.37 ± 2.59%  98.25 ± 0.03%  888.65 ± 0.22%  14.45 ± 1.47%  
 
4.1.2 Sequence analaysis of IgM 84 and 85 
4.1.2.1 Identifying N-glycosylation sites on IgM 84 and 85  
Part of the amino acid sequences of IgM 84 and 85 can be found in Appendix A. Six 
potential N-glycosylation sites were identified in heavy  chain constant regions (C1 to C4) 
of both IgM 84 and 85 (Table 4.2) . Interestingly, one additional potential N-glycosylation site 
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 In the representation of our results, standard deviation (SD) was expressed as %RSD or percentage of 
relative standard deviation instead of absolute numbers because we find that reproducibility of our 




was also identified in the light chain constant regions of both antibodies. This site was found at 
the tail-end of the light chain bearing the consensus amino acid sequence of Asn-Xaa-Cys (N-
X-C), which has not been reported for IgM so far (Table 4.2). Comparing the relative positions 
of these N-glycosylation sites, there is a side shift of 2 amino acids for N-glycosylation sites on 
the heavy chain; and 1 amino acid for that on the light chain between IgM 84 and 85. This is 
because IgM 84 has 2 amino acids less in the heavy chain variable regions and 1 amino acid 
less in the light chain variable regions than that of IgM 85. This observation is evident by the 
presence of gaps in the sequence alignment results shown in Appendix A. 
Table 4.2 Potential N-glycosylation sites of IgM 84 and 85 
IgM N-glycosylation sites 
IgM 84  
 Heavy chain 
 Light chain 
 
Asn-160, Asn-254, Asn-325, Asn-357,Asn-372, Asn-395 
Asn-211 
IgM 85  
 Heavy chain 
 Light chain 
 
Asn-158, Asn-252, Asn-323, Asn-355,Asn-370, Asn-393 
Asn-212 
 
4.1.2.2 Sequence alignment of IgM 84 and 85 
Table 4.3 shows the percentage sequence similarity resulting from sequence alignment of IgM 
84 and 85. The constant regions of IgM 84 and 85 were found to be 99.80% identical, except 
that IgM 84 has a threonine at position 291 whereas IgM 85 has a serine at position 289 on 
their respective heavy chains. The full sequence alignment results also showed that there are 3 
different gaps observed in IgM 84 due to the different lengths of IgM 84 and 85. Major 
differences between the two sequences lie in the variable regions of both heavy and light 
chains that is, sequence similarities are 51.30% (heavy), 64.82% (light) and 57.80% (both 




Table 4.3 Sequence similarities between IgM 84 and 85 constant and variable regions 
Domains of IgM Sequence similarity 
Full length IgM (monomer) 87.60% 
Heavy () chain 89.70% 
 Constant regions 99.77% 
 Variable regions 51.30% 
Light () chain 82.20% 
 Constant regions 100.00% 
 Variable regions 64.82% 
Constant regions 99.80% 





4.2 Characterization of the N-glycans of IgM 84 and 85 
4.2.1 Global N-glycan profiling 
In general, we found three main types of N-glycan on IgM 84 and 85 – high mannose, 
complex and hybrid types that we categorize them in four groups as shown in Table 4.4. Table 
4.4 summarized the percentage relative abundance (%RA) of high mannose, biantennary 
complex, triantennary complex, and hybrid types and showed only the top most abundant N-
glycan species within each group in terms of percentage distribution.  
As an overview, both IgM 84 and 85 share some similarities in terms of percentage 
relative intensities – high mannose type N-glycans being the most abundant N-glycan types i.e. 
from 67.3% to 82.5%, followed by complex type i.e. from 11.6% to 27.7%
1
 and hybrid the 
least i.e. from 5.3% - 7.3% (Table 4.4). In addition to that, according to percentage 
distribution, GlcNAc2Man6, GlcNAc2A2G3S1, GlcNAc2A3G4S1 and GlcNAc2A1Man5G1S’1 (see 
note of Table 4.4 for nomenclature) are among the most abundant N-glycan species within the 
respective N-glycan groups of both IgM 84 and 85. On the other hand, GlcNAc2A2G2S’1 was 
found to be the most abundant species in IgM 84 only; whereas FcGlcNAc2A2, 
FcGlcNAc2A2G3S’1, GlcNAc2A3G5S1 and FcGlcNAc2A3G3S’2 were observed to be the top most 
abundant species in IgM 85 only within the respective groups. With this information, we then 
explored further to elucidate the differences between IgM 84 and 85 in terms of the N-glycan 
types present in each of them.  
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 These figures are calculated by adding %relative intensities of biantennary and triantennary complex 




Table 4.4 Summary of differences between IgM 84 and 85 in terms of percentage relative 
abaundance (%RA) of four main groups of N-glycan and their percentage distributions (%D) 
within each group. Full list of N-glycan masses, structures, %RA and %D can be found in 
Appendix D. 
  





Run 1 Run 2 Run 1 Run 2 
1. High mannose         
  
%RA 70.4% 82.5% 67.3% 66.9% 
%D:         
1783.88 GlcNAc2Man6 67.0% 69.6% 71.1% 79.2% 
- Others 0.3 - 16.8% 0.3 - 15.8% 1.6 - 20.7% 1.1 - 16.0% 
2a. Biantennary complex type         
  
%RA 13.5% 8.4% 17.6% 20.5% 
%D:         
1835.93 FcGlcNAc2A2     14.1% 17.9% 
2461.22 GlcNAc2A2G2S’1 12.3% 14.7%     
2635.31 GlcNAc2A2G3S1 15.7% 17.0% 21.2% 25.8% 
2839.41 FcGlcNAc2A2G3S’1     13.4% 15.4% 
- Others 0.7 - 6.6% 0.6 - 6.8% 0.9 - 6.4% 0.6 - 4.1% 
2b. Triantennary complex type         
  
%RA 8.8% 3.2% 8.9% 7.2% 
%D:         
3084.54 GlcNAc2A3G4S1 13.3% 16.4% 13.3% 13.2% 
3288.64 GlcNAc2A3G5S1     13.7% 21.0% 
3475.72 FcGlcNAc2A3G3S’2     9.2% 10.5% 
- Others 1.0 - 8.8% 0.0 - 13.2% 1.0 - 6.2% 1.2 - 9.3% 
3. Hybrid          
  
%RA 7.3% 5.9% 6.2% 5.3% 
%D:         
2420.19 GlcNAc2A1Man5G1S’1 46.7% 54.5% 55.3% 51.8% 
- Others 2.3 - 21.3% 0.9 - 19.8% 2.3 - 21.3% 0.9 - 19.8% 
  Total %RA 100.0% 100.0% 100.0% 100.0% 
 
Note: A1, A2 and A3 represent trimannosyl core with one, two and three GlcNAc sugar units (or 
antenna), respectively; whereas Fc, G, S, S’ represent fucose, galactose, Neu5Ac and Neu5Gc 
sugar units, respectively; and B represents a bisecting GlcNAc sugar that is attached 1-4 to A 






Figure 4.2A High mannose N-glycan types on IgM 84 (left) and IgM 85 (right) 
Figure 4.2A shows the presence of high mannose type N-glycans on IgM 84 and IgM 
85. One difference between IgM 84 and 85 is the presence of Man9GlcNAc2 in IgM 84 
(indicated by red arrow), which is absent in IgM 85. In the biosynthetic pathway of N-glycans, 
high mannose N-glycan types are typically trimmed down to Man5GlcNAc2 in cis-Golgi before 
a GlcNAc sugar residue is added to form complex N-glycan types. Hence, the presence of 
Man9GlcNAc2 suggests that the trimming processes of high mannose type N-glycans in IgM 84 
are less mature than that in IgM 85. This may therefore result in a different protein 
conformation of IgM 84 compared to IgM 85 because the trimming process of Man9GlcNAc2 
to Man8GlcNAc2 occurs inside the Endoplasmic reticulum (ER) and N-glycosylation in ER 
plays an important role in how a protein is folded prior to the exit (Stanley et al., 2009).  
 
Figure 4.2B Asialylated biantennary complex N-glycan types on IgM 84 (left)  





Figure 4.2C Sialylated biantennary complex N-glycan types (biantennary) on IgM 84 (left)  
IgM 85 (right) 
Biantennary complex N-glycan types were categorized into asialylated groups in 
Figure 4.2B, and sialylated groups in Figure 4.2C. For ease of comparison, we paired up any 
two complex N-glycan types that differ by only one fucose that is attached to the proximal 
GlcNAc of the core structure via (1-6) linkage, which resulted in 10 structure pairs i.e. 5 
pairs in Figure 4.2B and 5 pairs in Figure 4.2C. These 10 structure pairs were presented at the 
top of both figures, while other structures were presented below, or nearer to the x-axes of 
mass spectra. Once this pairing comparison was done, it became clear that there is a major 
difference between IgM 84 and IgM 85 in fucosylation, which is one of the maturation steps in 
the biosynthesis of N-glycans. Overall, the N-glycans of IgM 84 are less fucosylated than 
those of IgM 85 as observed by the presence of five non-fucosylated biantennary complex N-
glycan types in IgM 84 (red boxes in Figures 4.2B and 4.2C), which are not present in IgM 85. 
Moreover, IgM 85 has two fucosylated biantennary complex N-glycan types (green boxes in 
Figures 4.2B and 4.2C), which are absent in IgM 84. The incomplete fucosylation in IgM 84 
could be explained by a difference in protein conformation of IgM 84 entering the Golgi 
apparatus that causes the N-glycosylation sites on IgM 84 bearing these complex N-glycan 
types to be shielded from enzymes that add fucose in the trans-Golgi. Besides, we observed 
three unique N-glycan types – one bisecting complex N-glycan type in IgM 85 only, and two 
sialylated biantennary complex N-glycan types in IgM 84 only (as indicated by red arrows in 





Figure 4.2D Asialylated and monosialylated trianntennary complex N-glycan types on IgM 84 
(left) and IgM 85 (right) 
 
Figure 4.2E Disialylated and trisialylated triantennary complex N-glycan types on  
IgM 84 (left) and IgM 85 (right) 
 
Figures 4.2D and 4.2E show the asialylated, mono-, di- and trisialylated triantennary 
complex N-glycan types of IgM 84 and 85.The triantennary complex N-glycans of IgM 84 
appear to be less fucosylated compared to those of IgM 85, similar to what was observed for 
biantennary complex N-glycan types. This claim was substantiated by the presence of two 
non-fucosylated triantennary complex N-glycan types (red boxes in Figure 4.2D) and absence 
of one fucosylated triantennary complex N-glycan type (green box in Figure 4.2E) in IgM 84, 
when compared with IgM 85. Besides, there are three unique triantennary complex N-glycan 
types – one disialylated triantennary complex N-glycan type in IgM 84 only, and two 
trisialylated triantennary complex N-glycan types in IgM 85only (as indicated by three red 




4.2.1.1 Detection of immunogenic glyco-epitopes 
As shown in Figures 4.2B – 4.2E, two glyco-epitopes, -Gal and Neu5Gc that are 
immunogenic to human (Galili, 2005; Padler-Karavani et al., 2008) were observed to be 
present in some N-glycans on IgM 84 and 85. We performed Western blot and confirmed the 
presence of these epitopes (Figure 4.3). Protein bands (between 80kDa and 100kDa) most 
likely correspond to the full heavy  chains of IgM 84 and 85, while bands (between 60kDa 
and 80kDa) are probably degraded heavy  chain fragments. Also, light chains of IgM 84 and 
85 were not detected in the following Western blot which indicates the absence of alpha gal 
and Neu5Gc epitopes on the light chains of the IgM. Interestingly, we also discovered an extra 
band (red arrow) that seems to suggest the presence of complex type N-glycan bearing 
Neu5Gc on the J-chain as confirmed on the other western blot using anti-J chain antibody 
(Figure 4.3 (right)).  
 
Figure 4.3 Western blots that detect presence of -Gal (left), Neu5Gc (middle) and  
J-chain (right) in both IgM 84 and 85. Numbers on the left indicate the  






Table 4.5 Positive and negative controls used in Western blot to detect glyco-epitopes of IgM 84 
and 85 
 Positive control (+) Negative control (-) 
-Gal Protein extract from mouse heart Ribonuclease B (Sigma Aldrich) 
Neu5Gc Fetuin (Sigma Aldrich) Ribonuclease B (Sigma Aldrich) 
J-chain Protein extract from mouse spleen (Santa Cruz) - 
 
4.2.1.2 Sialylation of IgM84 and 85 
From the results of N-glycan global profiling (Figure 4.2B – 4.2E), we observed the 
presence of asialylated, monosialylated, disialylated and trisialylated complex type N-glycans. 
In order to compare their relative amounts, we separated the complete pool of released N-
glycans by HPAEC-PAD. Thus, we obtained several population of N-glycans based on their 
extent of sialylation.  
  
Figure 4.4 Percentage of asialylated and sialylated N-glycans (left) and  
distribution of mono-, di-, and trisialylated N-glycans within the sialylated N-glycans pool (right) 
of IgM 84 and 85 
 
Figure 4.4 (left) showed that the percentage of sialylated N-glycans on IgM84 is lower 














Breakdown of %sialylated N-glycans 




contribution of different sialylated N-glycans, we plotted another bar chart (Figure 4.4 (right)) 
which showed that disialylated complex N-glycan types are the main contributors in both IgM 
84 and 85, followed by monosialylated and trisialylated N-glycans. These results were based 
on the same amount of protein (i.e. 100g) rather than the total sialylated N-glycans. In other 
words, to better cross-compare the relative contribution of each type of sialylated N-glycans, 
we normalized the individual types of %sialylated N-glycans in Figure 4.4 (right) by the total 
%sialylated N-glycans in Figure 4.4 (left). It was therefore observed that, for the same amount 
of total sialylated N-glycans, IgM 84 has more disialylated and less trisialylated than that of 
the IgM 85. Monosialylated N-glycans are almost the same in either sample (Figure 4.5).  
  
Figure 4.5 Breakdown of %sialylated N-glycans distribution of IgM 84 and 85. Color codes: green 
– trisialylated, blue – disialylated, peach – monosialylated 
 
 
Figure 4.6 Total sialic acid content [mol SA/mol of protein] of IgM 84 and 85 
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The total amount of sialic acid were quantified using a high throughput method 
recently developed by researcher at MIT in collaboration with our group (Raga et al., 2010). 
Results obtained in Figure 4.6 are average of three independant runs. In Figure 4.6, it is 
observed that total sialic acid content of IgM 85 is higher than that of IgM 84 by almost twice 
in absolute amount i.e. 21.74 ± 1.09 mol/mol IgM 85 and 12.32 ± 1.98 mol/mol for IgM 
84 (means of 3 independant experiments).It is also worth noting that the relative contribution 
of sialic acid types i.e. Neu5Gc and Neu5Ac is quite different in each of IgM 84 and 85. 
However, these results require further examination to conclude. 
These results showed that the sialylation – one of the late maturation steps in 
biosynthetic pathway of N-glycans  occuring in the trans-Golgi cisternae of IgM 84 may be 
less mature compared to IgM 85 due to lower percentage of total sialic acids (Figure 4.6) and 
relatively lower percentage of sialylated N-glycans (Figure 4.4 (left)). In addition, relatively 
more disialylated N-glycans (blue pie in Figure 4.5) and lesser trisialylated N-glycans (green 







4.2.2.1 Site-specific N-glycan profiling 
To identify the site-occupancy and type of N-glycans present at the different N-
glycosylation sites of IgM 84 and 85, IgM were digested into peptides and glycopeptides 
mixtures and separated using Sep-Pak® column. The interesting glycopeptides were further 
identified using MALDI-TOF/MS and MALDI-TOF-TOF/MS-MS. The full profiles of 
glycopeptides, peptides and amino acids after trypsin digestion can be found in Appendix D. In 
our first trial, we were able to identify one glycopeptide ion, T36 with sequence of 
IMESHFN395GTFSAK
+
 for IgM 84 bearing high mannose N-glycan types. To verify this, we 
identified four main mass peaks (red dotted lines) with a mass difference of 162Da, which 
corresponds to the mass of an hexose. The masses of these four main peaks (Table 4.6) match 
the calculated masses of the suggested structures.  
 




162 162 162 
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Table 4.6 Masses of four main peaks (red dotted lines) 
Mass Peak Mass (Da) Structure 
1 2634.98 T36-Man5GlcNAc2 
2 2796.83 T36-Man6GlcNAc2 
3 2958.85 T36-Man7GlcNAc2 
4 3120.88 T36-Man8GlcNAc2 
 
Other subpeaks adjacent to the main peaks serve as a confirmation that these main 
mass peaks are indeed glycopeptide ions. For instance, the mass difference of 16Da indicates 
the extra mass added to peptide T36 due to oxidation of methionine, and 22Da indicates adduct 
Na
+
 ion of glycopeptides. Further fragmentation of these peaks yielded mass peaks of the 
fragments of the suggested structure. When mass peak #2 (highest intensity in Figure 4.7A) 
was subjected to MS-MS, we indeed observed mass peaks that correspond to the fragments of 
the suggested structures (brown dotted lines in Figure 4.7B). Thus we could confirm the 
presence of high mannose N-glycan types Man5-8GlcNAc-N395 on glycopeptide T36 of IgM 84. 
 



















4.3 Comparative modeling of IgM84 and 85 
4.3.1 Template identification 
Using Discovery Studio, we use BLAST against DS Server to search for templates of 
variable regions of IgM 84 and 85 for individual heavy and light chains. Templates with 
highest bit scores and lowest E-values (Table 4.7) were selected for sequence alignment. The 
selected protein templates were found to originate from mouse. Although IgM 84 and 85 are 
produced in mouse hybridoma, these results were simply coincident and not part of the 
selection criteria, as earlier mentioned in Section 2.6. 
Table 4.7 Template identified with highest bit score and lowest E-value for each of the variable 
regions of IgM 84 and 85 
No Target Template Organism Bit score E-value 
1 IgM 84_V
H
 1SM3_H House mouse 193.4 6.5x10-51 
2 IgM 85_V
H
 1NLD_H House mouse 204.1 3.8x10-54 
3 IgM 84_V
L
 1AY1_L House mouse 186.0 9.5x10-49 
4 IgM 85_V
L
 2FGB_A House mouse 202.2 1.3x10-53 
 
4.3.2 Sequence alignment 
We next re-aligned the protein sequences with their corresponding templates. Table 
4.8 shows that the target-template sequence alignment has a high percentage of sequence 





Table 4.8 Target-template sequence alignment results for each of the variable regions of IgM 84 
and 85 






 1SM3_H 94.0% 94.9% 
2 IgM 85_V
H
 1NLD_H 86.1% 91.3% 
3 IgM 84_V
L
 1AY1_L 91.6% 97.2% 
4 IgM 85_V
L
 2FGB_A 93.5% 97.2% 
 
4.3.3 Model building 
Using MODELER, five models were created for each target-template aligned 
sequence. Each of these models returned a different value for PDF Total and Physical Energy 
and DOPE. The model with the lowest PDF energies and DOPE Score (most negative) 
suggests the best created model for a particular target (Table 4.9).  
Table 4.9 Best models for variable regions of IgM 84 and 85 based on lowest PDF energies and 
DOPE Score 









 1SM3_H 518.1 315.9 -11257.4 
2 IgM 85_V
H
 1NLD_H 569.7 328.8 -11605.5 
3 IgM 84_V
L
 1AY1_L 554.9 318.2 -9522.7 
4 IgM 85_V
L






Heavy variable regions (VH) of IgM84 and 85 
 
Figure 4.8 IgM 84_VH (left) and IgM 85_VH (right) 
Light variable regions (VL)of IgM84 and 85 
 
Figure 4.9 IgM 84_VL (left) and IgM 85_VL (right) 
Figure 4.8 shows the best models for IgM 84 and 85 variable heavy chain domains. 
The portions, which are highlighted in yellow (left of Figure 4.8) and in green (right of Figure 
4.8), depict the Complementarity Determining Regions (CDRs) of IgM 84 and 85 variable 
heavy chains, respectively. Similarly, we have identified the CDRs for IgM 84 and 85 variable 




4.3.4 Model Validation 
To verify the reliability of these models, we performed Verify Protein (Profiles-3D) 
protocol under Discovery Studio, and Molprobity, open and web-based validation software 
(http://molprobity.biochem.duke.edu/).  
4.3.4.1 Verify Protein (Profiles-3D) 
Table 4.10 Verify scores for the best model of each target sequence of IgM 84 and 85 
No Model Verify Expected 
Low Score 
Verify Score 




 23.2 53.6 51.5 
2 IgM85_V
H
 23.2 55.4 51.5 
3 IgM84_V
L
 21.7 52.6 48.3 
4 IgM85_V
L
 21.7 48.4 48.3 
 
In order for a model to be reliable, the calculated verify score for each model has to be 
higher than the verify expected high score, and much higher than the verify expected low score 
that are generated when calculating the verify score. According to these specifications, our 





4.3.4.2 Molprobity (Ramachandran Plot) 
 
Figure 4.10 Ramachandran Plots for IgM 84_VH (left) and IgM 85_VH (right) 
 
Figure 4.11 Ramachandran Plots for IgM 84_VL (left) and IgM 85_VL (right) 
Ramachandran plots measure and visualize the dihedral angles  and  of amino acid 
residues in protein backbones. In order for a protein model structure to be considered reliable, 
most of the amino acid residues (indicated by open circles in figures 4.10 and 4.11) are 
required to fall within the favored regions (outlined by light blue lines) and few within the 
allowed regions (outlined in purple lines). However, if too many of the amino acid residues are 
found outside of these two regions, they might be under too much stress as they are forced to 









85_VH, Ser77 of IgM 84_VL and IgM 85_VL, fall within the two regions we just mentioned, 
which is consistent with the results obtained from Verify Protein (Profiles-3D) protocol. 
4.3.5 Model superimposition 
To compare the structural differences between variable regions of IgM 84 and 85, we 
superimposed their structures using Align and Superimpose Proteins protocol and results are 
shown in Figure 4.12. The main differences lie in the four loop regions – three on the CDRs 
(white circles) and one between two -sheets (orange circle) in both model superimpositions. 
Other parts of the variable domains are structurally similar. Results of RMSD of variable 
heavy and light regions are below 3.5 Å (Table 4.11), which is indicative of significant fold 
similarity and possible structural homology (Cuff, A et al. 2008). Hence, we concluded that 
there is a lack of evidence to suggest any structural differences between the variable regions of 
IgM 84 and 85.  
  
Figure 4.12 Model superimposition of two variable regions – heavy chains (left) and light chains 
(right) of IgM 84 and 85 
 
Table 4.11 RMSD of model superimposition of the heavy chain and light chain variable regions of 
IgM 84 and 85 
Protein domains RMSD (Å) 
Heavy variable regions (VH) 1.51 




5 CONCLUSIONS AND RECOMMENDATIONS 
5.1 Conclusions 
The N-glycan analysis described in this thesis showed that the N-glycans of IgM 84 are 
less mature than those of IgM 85. This was evident from the presence of the immature high 
mannose type N-glycan Man9GlcNAc2, more non-fucosylated complex type N-glycans, lower 
overall degree of sialylation in IgM 84. The incomplete trimming of high mannose type N-
glycans during the early stage of post-translational modifications causes IgM 84 to be 
differently folded as compared to IgM 85 because N-glycosylation plays an important role in 
protein folding in the endoplasmic reticulum (ER). Furthermore, the presence of various bi- 
and triantennary complex type N-glycan structures in IgM 84 that are non-fucosylated could 
also point to a less mature fucosylation in IgM 84 compared to that of IgM 85. This could then 
be due to a difference in protein folding between IgM 84 and 85 exiting the ER, i.e. shielding 
the structures at certain N-glycosylation sites from fucosylation during the late stage of post-
translational modification. We also observed that the N-glycans of IgM 84 are generally less 
sialylated, besides the presence of two trisialylated complex type N-glycans that are unique to 
IgM 84, which lead to the possibility that sialylation of IgM 84 is also less mature compared to 
that of IgM 85.In summary, we suggest that the difference in mannose trimming and in 
fucosylation and sialylation are the effect resulted from the differently folded IgM 84 and 85 
proteins. We propose that this difference in protein conformation of IgM 84 may attribute to 
the cytotoxic nature of IgM against undifferentiated human embryonic stem cells (hESCs) as it 
was previously suggested that multivalency of pentameric IgM 84 plays an important role in 
cytotoxicity effect (Lim et al., 2011).  
Our 3D models of the variable binding of IgM 84 and 85 have demonstrated that the 
structural differences between IgM 84 and 85 in their antigen binding sites are subtle, although 
differences in their primary sequences had led us to think otherwise. This finding further 




with single-valence binding of antigen sites (Lim et al., 2011), possibly due to the structural 
similarities between the variable binding sites of IgM 84 and 85 as suggested by our models. 
Though four loop regions are identified to be different upon superimposition, we are sceptical 
that such difference around the connecting loop could cause such a big difference in terms of 
cytotoxic functionality of the IgM 84. 
In conclusion, our 3D models first discounted the possibility that any explanation to the 
cytotoxicity of IgM 84 was due to its antigen binding sites alone. In addition, our findings 
about the differences in N-glycosylation maturation between IgM 84 and 85 further suggest a 
differently folded IgM 84 that may attribute to its cytotoxic nature against undifferentiated 
hESCs. 
 
5.2 Recommendations for Future Work 
Following the work from this thesis, we recommend proceeding to identify the site 
specific differences of IgM 84 and 85 in terms of N-glycosylation. Though we have already 
identified a single site on IgM 84 that possesses high mannose type N-glycans, more work is 
required to elucidate the types of N-glycans that are present on each potential N-glycosylation 
site of both IgM 84 and 85. To do so, we propose to fractionate and analyze the individual 
glycopeptides (Appendix C) directly using liquid chromatography-mass spectrometry (LC-
MS) to reduce sample loss during sample preparation steps and obtain enough resolution for 
having a good separation of all the glycopeptides, before we could complete this work. With 
such information on site-occupancy, it would allow us to shed more light on the different 
protein conformations of IgM 84 and 85. In addition, we would also continue our work on 
comparative modeling of the full pentameric IgM 84 and 85, as well as some experimental 
studies on their respective protein conformations, to demonstrate our hypothesis that the defect 
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APPENDIX A:  Sequence analysis of IgM 84 and 85 
Partial amino acid sequences of heavy and light chains of IgM 84 and 85 are shown as 
follows i.e. Seq1, Seq2, Seq3 and Seq4. Amino acids are represented by the 1-letter code. For each 
sequence, variable regions are underlined; potential N-glycosylation sites are highlighted in red i.e. 
NNT, NFT, NVS, NLT, NIS, NGT and NEC; and complementarity determining regions (CDRs) are 
highlighted in green. Heavy chains of IgM 84 and 85 have 551 and 549 amino acids, respectively, 
whereas light chains of IgM 84 and 85 have 213 and 214 amino acids, respectively.  



















Seq3. Partial heavy chain sequence of IgM 85 
1  QVKLQESGPGLVQPSQSLSITCTVSGFSLTGYGLHWVRQSPGKGLEWLGVIWRGGNTDYN 
 
61  AAFMSRLSITKDNSKSQVFFKMNSLQADDTAIYYCARDFDYWGQGTTVTVSSESQSFPNV 
 
















Sequence alignment between constant and variable regions of IgM 84 and 85 are shown as 
follows i.e. SA1 and SA2 respectively. We highlighted the portion light chains of these regions in 
brown and the CDRs in green. The constant regions are almost identical i.e. 99.82% sequence 
identity except for one amino acid at position 177 (highlighted in red) i.e. IgM 84 has a theorine (Thr 
or T) and IgM 85 has a serine (Ser or S). The main difference between primary amino acid sequences 
of IgM 84 and 85 therefore, comes from variable regions i.e. 57.85% sequence identity, in particular 
the CDRs.  
SA1. Segment of alignment between constant regions of IgM 84 and 85 
               10        20        30        40        50        60 
IgM84  ESQSFPNVFPLVSCESPLSDKNLVAMGCLARDFLPSTISFTWNYQNNTEVIQGIRTFPTL 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
IgM85  ESQSFPNVFPLVSCESPLSDKNLVAMGCLARDFLPSTISFTWNYQNNTEVIQGIRTFPTL 
               10        20        30        40        50        60 
 
              130       140       150       160       170       180 
IgM84  RDGFSGPAPRKSKLICEATNFTPKPITVSWLKDGKLVESGFTTDPVTIENKGSTPQTYKV 
       ::::::::::::::::::::::::::::::::::::::::::::::::::::::::.::: 
IgM85  RDGFSGPAPRKSKLICEATNFTPKPITVSWLKDGKLVESGFTTDPVTIENKGSTPQSYKV 
              130       140       150       160       170       180 
 
              430       440       450       460       470       480 
IgM84  ALPHLVTERTVDKSTGKADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKID 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
IgM85  ALPHLVTERTVDKSTGKADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKID 
              430       440       450       460       470       480 
 
           
IgM84  NEC 
       ::: 
IgM85  NEC 
 
Note: There are three symbols represented by sequence alignment results i.e ‘:’ means two aligned amino 
acids are identical; ‘.’ means two aligned amino acids are similar but not identical; ‘ ’ means two aligned 
amino acids are neither identical nor similar.  
SA2. Segment of alignment between variable regions of IgM 84 and 85 variable regions 
               10        20        30        40        50        60 
IgM84  QVQLQQSGGGLVQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRLKSNNYAT 
       ::.::.:: :::::. :....:..:::....: ..:::::: :::::.. :   .:   : 
IgM85  QVKLQESGPGLVQPSQSLSITCTVSGFSLTGYGLHWVRQSPGKGLEWLGVIWRGGN---T 





     120       130       140        150       160       170      
IgM84  QSPAIMSASPGEKVTMTCSASSSV-NYMYWYQQKPGSSPRLLIYDTSNLASGVPVRF... 
       :::. .::: ::.:..:: ::. . .:. : :::: .. . ::: .:.: :::: :: 
IgM85  QSPSSLSASLGERVSLTCRASQEISDYLSWLQQKPDGTIKRLIYAASTLDSGVPKRF... 
       120       130       140       150       160       170     
 
          200       210       220 
IgM84  ...YYCQQWSSYPYTFGGGTKLEIKR 
          ::: :.::.:::::::::::::: 
IgM85  ...YYCLQYSSHPYTFGGGTKLEIKR 
          200       210       220 
 
Note: There are three symbols represented by sequence alignment results i.e ‘:’ means two aligned amino 
acids are identical; ‘.’ means two aligned amino acids are similar but not identical; ‘ ’ means two aligned 
amino acids are neither identical nor similar.  




APPENDIX B. N-linked glycan profiling resources 
Table B1. N-linked glycan profiling data for all mouse cell types available from Consortium for 
Functional Glycomics (CFG) resources 
Mouse Cell Type  Comments Participating Investigator 
A9 fibroblasts  A9 fibroblasts  
Agbandje-McKenna, Mavis 
SV40 transformed fibroblast cell 
line, NB324K  
SV40 transformed fibroblast cell 
line, NB324K, NG 
EL4 T lymphocytes EL4 T lymphocytes, NG  
A9 fibroblasts  A9 fibroblasts, NG  
SV40 transformed fibroblast cell 
line, NB324K  
SV40 transformed fibroblast cell 
line, NB324K, NG  
Neutrophils  Mouse Neutrophils  
Cummings,Richard D. 
WEHI-3  Murine WEHI-3  
Murine mammary carcinoma  4T07 p.20 7-21-05  
Rittenhouse-Olson, Kate Murine mammary carcinoma  67NR p.22 7-25-05  
Murine mammary carcinoma  4TI p.31 7-21-05  






IL-4 treated thioglycolate 
macrophages  
WEHI 231 B Cells WEHI 231 B Cells, Control  
Cook-Mills, Joan 
WEHI 231 B Cells 
WEHI 231 B Cells, Test 
(apoptotic)  
WEHI 231 B Cells 
WEHI 231 B Plasma Membranes, 
Control  
WEHI 231 B Cells 
WEHI 231 B Plasma Membranes, 





Table B2. Mouse N-linked glycan profiling data for all mouse cell types available from Consortium for 
Functional Glycomics (CFG) resources 
Cell Type  Comments  Participating Investigator 
Cytokine-induced killer (CIK) 
cells 
Cytokine-induced killer (CIK) 
cells, Unsorted  
Contag, Christopher 
Cytokine-induced killer (CIK) 
cells 
Cytokine-induced killer (CIK) 
cells, NKG2D Treated  
Eosinophils  
Eosinophils (EOS), IL5 Tg mice 
(NJ1638) E782  
Paulson, James 
Eosinophils 
Eosinophils (EOS), IL5 Tg mice 
(NJ1638) E793  
Osteoclasts  
Osteoclast Cells, Mouse 2, 
Control, NG  
Wu, Hui 
Osteoclasts  
Osteoclast Cells, Mouse 1, 
RANKL, NG  
Osteoclasts  
Osteoclast Cells, Mouse 1, 
Tunicamycin, NG  
Osteoclasts  
Osteoclast Cells, Mouse 1, 
RANKL+Tunicamycin, NG  
Osteoclasts  
Osteoclast Cells, Mouse 2, 
Control, NG  
Osteoclasts  
Osteoclast Cells, Mouse 2, 
RANKL, NG  
Osteoclasts  
Osteoclast Cells, Mouse 2, 
Tunicamycin, NG  
Osteoclasts  
Osteoclast Cells, Mouse 2, 
RANKL+Tunicamycin, NG 
B1 Cells  
Murine B1 cells (peritoneal 
cavity), mouse A (MB1/A), NG  
Nitschke, Lars 
B1 Cells  
Murine B1 cells (peritoneal 
cavity), mouse B (MB1/B), NG  
B1 Cells  
Murine B2 cells (spleen), mouse 
A (MB2/A), NG  
B1 Cells  
Murine B2 cells (spleen), mouse 
B (MB2/B), NG  
Antibodies 
Murine antibodies, LN 2-4G2, 
NG  





Table B3. Mouse N-linked glycan profiling data for all mouse spleen tissues available from Consortium 
for Functional Glycomics (CFG) resources 
Mouse Strain  Mice Colony Code  Mouse Type  
Wild type  N.A. C57BL/6 
Fuct IV FA C57BL/6 
Fuct VII FB C57BL/6 
Fuct IV + VII FC C57BL/6 
Gal 3 GT C57BL/6 
ST3 Gal 1 ST C57BL/6 
CT GalNAcT  N.A. C57BL/6 





APPENDIX C. Glycopeptide sequences of digested IgM 84 and 85 
IgM 84 and 85 that are completely digested with trypsin result in pools of glycopeptides, 
peptides and amino acids. Table C1, C2, C3 and C4 show the theoretical sequences of these 
glycopeptides, peptides and amino acids analyzed from the enzymatic action of trypsin, which lyzes 
the C-terminal of lysine (Lys or K) or arginine (Arg or R) except for those that are immediately 
followed by proline (Pro or P). The sequences are presented in 1-letter code of amino acids. Again, 
potential N-glycosylation sites are highlighted in red i.e. in T12, T23, T31, T32 and T34 of IgM 85 
heavy chain; T21 of IgM 85 light chain; T14, T25, T33, T34 and T36 of IgM 84 heavy chain; and T18 
of IgM 84 light chain.  
Table C1. Selected list of amino acid sequences of glycopeptides, peptides and amino acids of IgM 85 full 
heavy chain after trypsin digestion  























Table C2. Selected list of amino acid sequences of glycopeptides, peptides and amino acids of IgM 85 full 
light chain after trypsin digestion 







Table C3. Selected list of amino acid sequences of glycopeptides, peptides and amino acids of IgM 84 full 
heavy chain after trypsin digestion 



















Table C4. Selected list of amino acid sequences of glycopeptides, peptides and amino acids of IgM 84 full 
light chain after trypsin digestion 










APPENDIX D. Masses, structures, percentages of relative 
abundance and distribution of all N-glycans on IgM 84 and 85 
We categorized all the N-glycan structures in four groups – high mannose, biantennary, 
triantennary complex and hybrid structures as shown in Table D1 and D2. Mass peaks obtained 
experimentally from MALDI-TOF MS are of mass accuracies
1
 within range of 0.0022 – 0.0134% 
(IgM 84) and 0.0038 – 0.0203%. (IgM 85). The absolute intensities of the mass peaks were chosen to 
calculate the percentage relative abundance (%RA) and percentage distributions (%D) according to 
formulae described in Section 3.2.7.1.  
Table D1. Percentage relative abundance (%RA) and percentage distribution (%D) of all N-glycans of 
IgM 84 measured by MALDI-TOF MS of two independent runs i.e. Run 1 and Run 2 
 
  Run 1 Run 2 
N-glycan 
masses 
N-glycan structures %RA %D %RA %D 
High mannose 
1579.78 GlcNAc2Man5 11.8% 16.8% 13.1% 15.8% 
1783.88 GlcNAc2Man6 47.2% 67.0% 57.4% 69.6% 
1987.98^ GlcNAc2Man7 9.2% 13.1% 10.1% 12.2% 
2192.08^ GlcNAc2Man8 2.0% 2.8% 1.9% 2.3% 
2396.18 GlcNAc2Man9 0.2% 0.3% 0.1% 0.2% 
  Subtotal 70.4%   82.5%   
Biantennary complex type 
1590.80 FcGlcNAc2A1 0.3% 2.2% 0.2% 2.9% 
1661.84 GlcNAc2A2 0.2% 1.6% 0.1% 1.2% 
1835.93 FcGlcNAc2A2 0.8% 5.9% 0.5% 6.1% 
1865.94 GlcNAc2A2G1 0.4% 3.0% 0.2% 2.8% 
1981.98 GlcNAc2A1G1S1 0.1% 1.0% 0.1% 1.2% 
2040.03 FcGlcNAc2A2G1 0.4% 3.3% 0.3% 3.1% 
2070.04 GlcNAc2A2G2 0.9% 6.6% 0.5% 6.3% 
2186.08 FcGlcNAc2A1G1S’1 0.4% 2.9% 0.3% 3.5% 
2244.13 FcGlcNAc2A2G2 0.8% 6.3% 0.6% 6.8% 
2315.16 GlcNAc2A2BG2 0.3% 2.0% 0.1% 1.1% 
2431.21^ FcGlcNAc2A2G1S’1 0.6% 4.2% 0.4% 4.9% 
2448.22^ FcGlcNAc2A2G3 0.6% 4.8% 0.4% 4.4% 
2461.22 GlcNAc2A2G2S’1 1.7% 12.3% 1.2% 14.7% 
2478.24^ GlcNAc2A2G4 0.6% 4.7% 0.2% 2.0% 
                                                     
1




2489.25 FcGlcNAc2A2BG2 0.4% 2.8% 0.2% 2.0% 
2605.30 FcGlcNAc2A2G2S1 0.5% 3.6% 0.3% 4.0% 
2635.31^ GlcNAc2A2G3S1 2.1% 15.7% 1.4% 17.0% 
2665.32 GlcNAc2A2G3S’1 0.7% 5.3% 0.5% 6.1% 
2809.40^ FcGlcNAc2A2G3S1 0.3% 2.3% 0.2% 1.8% 
2839.41^ FcGlcNAc2A2G3S’1 0.6% 4.5% 0.3% 3.8% 
2852.40 GlcNAc2A2G2S’2 0.3% 2.0% 0.1% 1.8% 
2996.48 FcGlcNAc2A2G2S1S’1 0.1% 0.7% 0.0% 0.6% 
3026.49 FcGlcNAc2A2G2S’2 0.3% 2.2% 0.2% 1.8% 
  Subtotal 13.5%   8.4%   
Triantennary complex type 
2519.26 GlcNAc2A3G3 0.5% 5.7% 0.2% 7.1% 
2693.35^ FcGlcNAc2A3G3 0.8% 8.8% 0.4% 13.2% 
2880.44 GlcNAc2A3G3S1 0.3% 3.2% 0.1% 4.2% 
2897.45^ FcGlcNAc2A3G4 0.5% 6.0% 0.2% 7.6% 
2910.45 GlcNAc2A3G3S’1 0.4% 4.2% 0.2% 6.1% 
3054.52^ FcGlcNAc2A3G3S1 0.5% 6.0% 0.2% 6.6% 
3084.54^ GlcNAc2A3G4S1 1.2% 13.3% 0.5% 16.4% 
3101.55^ FcGlcNAc2A3G5 0.6% 6.7% 0.2% 4.8% 
3241.61^ GlcNAc2A3G3S2 0.1% 1.0% 0.0% 0.0% 
3258.62^ FcGlcNAc2A3G4S1 0.5% 5.3% 0.2% 5.3% 
3271.62 GlcNAc2A3G3S1S’1 0.2% 1.8% 0.0% 0.0% 
3288.64^ GlcNAc2A3G5S1 0.6% 6.5% 0.2% 6.9% 
3301.63 GlcNAc2A3G3S’2 0.2% 1.9% 0.0% 1.6% 
3305.65^ FcGlcNAc2A3G6 0.4% 4.0% 0.0% 0.0% 
3415.70 FcGlcNAc2A3G3S2 0.1% 1.5% 0.1% 1.9% 
3445.71^ GlcNAc2A3G4S2 0.3% 3.5% 0.1% 2.7% 
3462.72^ FcGlcNAc2A3G5S1 0.4% 4.4% 0.1% 2.5% 
3475.72^ FcGlcNAc2A3G3S’2 0.4% 4.8% 0.1% 3.4% 
3492.73^ FcGlcNAc2A3G5S’1 0.3% 4.0% 0.1% 2.3% 
3619.80^ FcGlcNAc2A3G4S2 0.1% 1.5% 0.0% 1.5% 
3649.81 FcGlcNAc2A3G4S’1S1 0.2% 2.2% 0.1% 2.1% 
3679.82 FcGlcNAc2A3G4S’2 0.2% 2.2% 0.1% 2.2% 
3866.90 FcGlcNAc2A3G3S’3 0.1% 1.3% 0.1% 1.7% 
  Subtotal 8.8%   3.2%   
Hybrid and others 
1824.91 GlcNAc2A1Man5 1.4% 19.8% 0.8% 14.2% 
2029.01 GlcNAc2A1Man5G1 1.6% 21.3% 1.2% 19.8% 
2216.09 GlcNAc2A1Man4G1S’1 0.7% 9.9% 0.6% 10.6% 
2420.19 GlcNAc2A1Man5G1S’1 3.4% 46.7% 3.2% 54.5% 










Note: A1, A2 and A3 represent trimannosyl core with one, two and three GlcNAc sugar units (or antenna), 
respectively; whereas Fc, G, S, S’ represent fucose galactose, Neu5Ac and Neu5Gc sugar units, 
respectively; and B represents a bisecting GlcNAc sugar that is attached 1-4 to A trimannosyl core. 
Subscript of each sugar shows the number of sugar units that are attached. *Mass peak of 3041.53 is a 
biantennary complex type N-glycan with a Le
a
 epitope, however the presence of this structure requires 
further confirmation by western blot. ^N-glycan masses require further fragmentation by MALDI-TOF-
TOF MS/MS to elucidate the structure. 
 
Table D2. Percentage relative abundance (%RA) and percentage distribution (%D) of all N-glycans of 
IgM 85 measured by MALDI-TOF MS of two independent runs i.e. Run 1 and Run 2 
  
Run 1 Run 2 
N-glycan 
masses 
Structure %RA %D %RA %D 
High mannose 
1579.78 GlcNAc2Man5 13.9% 20.7% 10.7% 16.0% 
1783.88 GlcNAc2Man6 47.8% 71.1% 53.1% 79.2% 
1987.98^ GlcNAc2Man7 4.5% 6.6% 2.5% 3.7% 
2192.08^ GlcNAc2Man8 1.1% 1.6% 0.7% 1.1% 
  Subtotal 67.3%   66.9%   
Biantennary complex type 
1590.80 GlcNAc2A1 0.6% 3.4% 0.5% 2.5% 
1835.93 FcGlcNAc2A2 2.5% 14.1% 3.7% 17.9% 
2040.03 FcGlcNAc2A2G 0.7% 3.7% 0.8% 3.9% 
2186.08 FcGlcNAc2A1G1S’1 0.3% 1.7% 0.3% 1.4% 
2244.13 FcGlcNAc2A2G2 0.5% 3.1% 0.5% 2.2% 
2285.15 FcGlcNAcA2BG1 0.4% 2.1% 0.4% 1.8% 
2448.22^ FcGlcNAc2A2G3 0.8% 4.5% 0.7% 3.3% 
2461.22^ GlcNAc2A2G2S*1 0.6% 3.1% 0.5% 2.6% 
2478.24^ GlcNAc2A2G4 0.3% 1.8% 0.2% 1.1% 
2489.25 FcGlcNAc2A2BG2 0.5% 2.9% 0.5% 2.6% 
2605.30 FcGlcNAc2A2G2S1 0.5% 2.7% 0.5% 2.3% 
2635.31^ GlcNAc2A2G3S1 3.7% 21.2% 5.3% 25.8% 
2652.32^ FcGlcNAc2A2G4 1.1% 6.4% 0.8% 4.1% 
2665.32 GlcNAc2A2G3S’1 0.8% 4.4% 0.8% 3.9% 
2809.40^ FcGlcNAc2A2G3S1 0.8% 4.4% 0.7% 3.4% 
2839.41^ FcGlcNAc2A2G3S’1 2.4% 13.4% 3.2% 15.4% 
2852.40 GlcNAc2A2G2S’2 0.3% 1.7% 0.3% 1.3% 
2996.48 FcGlcNAc2A2G2S1S’1 0.2% 0.9% 0.1% 0.6% 
3026.49 FcGlcNAc2A2G2S’2 0.8% 4.4% 0.8% 3.7% 
  Subtotal 17.6%   20.5%   
Triantennary complex type 
2693.35^ FcGlcNAc2A3G3 0.3% 3.5% 0.2% 3.3% 
2897.45^ FcGlcNAc2A3G4 0.3% 3.8% 0.2% 3.1% 




3054.52^ FcGlcNAc2A3G3S1 0.2% 2.7% 0.2% 2.3% 
3084.54^ GlcNAc2A3G4S1 1.2% 13.3% 1.0% 13.2% 
3101.55^ FcGlcNAc2A3G5 0.6% 6.2% 0.1% 1.6% 
3258.62^ FcGlcNAc2A3G4S1 0.4% 4.6% 0.3% 3.8% 
3271.62 GlcNAc2A3G3S1S’1 0.1% 1.6% 0.1% 1.2% 
3288.64^ GlcNAc2A3G5S1 1.2% 13.7% 1.5% 21.0% 
3301.63^ GlcNAc2A3G3S’2 0.1% 1.6% 0.1% 1.6% 
3305.65^ FcGlcNAc2A3G6 0.5% 5.9% 0.2% 2.6% 
3445.71^ GlcNAc2A3G4S2 0.3% 3.0% 0.2% 2.1% 
3462.72^ FcGlcNAc2A3G5S1 0.5% 5.7% 0.3% 4.4% 
3475.72^ FcGlcNAc2A3G3S’2 0.8% 9.2% 0.8% 10.5% 
3492.73^ FcGlcNAc2A3G5S’1 0.6% 7.2% 0.5% 6.4% 
3619.80^ FcGlcNAc2A3G4S2 0.1% 1.7% 0.1% 1.4% 
3649.81 FcGlcNAc2A3G4S’1S1 0.3% 3.0% 0.2% 2.5% 
3679.82 FcGlcNAc2A3G4S’2 0.5% 5.3% 0.7% 9.3% 
3806.88 FcGlcNAc2A3G3S2S’1 0.1% 1.0% 0.1% 1.4% 
3836.89 FcGlcNAc2A3G3S1S’2 0.1% 1.4% 0.1% 2.0% 
3866.90 FcGlcNAc2A3G3S’3 0.3% 3.2% 0.4% 4.9% 
  Subtotal 8.9%   7.2%   
Hybrid and others 
1824.91 GlcNAc2A1Man5 0.8% 13.1% 0.3% 4.6% 
2029.01 GlcNAc2A1Man5G1 0.8% 12.6% 0.4% 5.2% 
2216.09 GlcNAc2A1Man4G1S’1 0.7% 11.2% 0.7% 9.8% 
2420.19 GlcNAc2A1Man5G1S’1 3.4% 55.3% 3.7% 51.8% 
2418.21* FcGlcNAc2A2FcG2 0.3% 4.3% 0.1% 1.4% 





  Total 100.0% 100.0% 
 
Note: A1, A2 and A3 represent trimannosyl core with one, two and three GlcNAc sugar units (or antenna), 
respectively; whereas Fc, G, S, S’ represent fucose, galactose, Neu5Ac and Neu5Gc sugar units, 
respectively; and B represents a bisecting GlcNAc sugar that is attached 1-4 to A trimannosyl core. 
Subscript of each sugar shows the number of sugar units that are attached. *Mass peaks of 2418.21 
3041.53 are biantennary complex type N-glycans with a terminal Le
a
 epitope, however the presence of 
these structures requires further confirmation by western blot. ^N-glycan masses require further 
fragmentation by MALDI-TOF-TOF MS/MS to elucidate the structure. 
